The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

8-2014

Development of a New Independent Monte Carlo Dose
Calculation Quality Assurance Audit Tool for Clinical Trials
Austin M. Faught

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Medical Biophysics Commons, and the Other Physics Commons

Recommended Citation
Faught, Austin M., "Development of a New Independent Monte Carlo Dose Calculation Quality Assurance
Audit Tool for Clinical Trials" (2014). The University of Texas MD Anderson Cancer Center UTHealth
Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 486.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/486

This Dissertation (PhD) is brought to you for free and
open access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

DEVELOPMENT OF A NEW INDEPENDENT MONTE CARLO DOSE CALCLUATION
QUALITY ASSURANCE AUDIT TOOL FOR CLINICAL TRIALS

By
Austin Michael Faught

Approved:

David Followill, Ph.D.
Advisory Professor

Geoffrey Ibbott, Ph.D.

Stephen Kry, Ph.D.

Scott Davidson, Ph.D.

Carol Etzel, Ph.D.

Approved:

Dean, The University of Texas
Health Science Center at Houston
Graduate School of Biomedical Sciences

DEVELOPMENT OF A NEW INDEPENDENT MONTE CARLO DOSE CALCLUATION
QUALITY ASSURANCE AUDIT TOOL FOR CLINICAL TRIALS

A
Dissertation

Presented to the Faculty of
The University of Texas Health Science Center at Houston
Graduate School of Biomedical Sciences
and
The University of Texas
MD Anderson Cancer Center

In Partial Fulfillment
of the Requirements
for the Degree of

Doctor of Philosophy

By

Austin Michael Faught
Houston, Texas
August, 2014

Acknowledgements
There are many people who have contributed their time, effort, and support in order for this
project to be completed. For that, I am grateful to you all. Special acknowledgement is
deserved by a few individuals for their extraordinary contributions. First, I am thankful for the
support of my parents, Mike and Lori, who have encouraged me in all my endeavors. Two great
educators played a significant role in my path towards Medical Physics. Rich Koehler, my high
school science teacher, first ignited the flame of curiosity within me, and Dr. John Idoine, a
physics professor at Kenyon College, introduced me to Medical Physics and mentored me
throughout my undergraduate work. Dr. Rich Popple and Dr. Jonas Fontenot generously
contributed their time to help with phantom measurements at their respective institutions. My
advisory committee has graciously provided me with their time and guidance during this
project. Dr. David Followill’s role as a mentor early in my Medical Physics career has been
invaluable. Finally, my soon to be wife, Jacqueline Tonigan has been a never ending source of
encouragement.

Development of a New Independent Monte Carlo Dose Calculation Quality Assurance
Audit Tool for Clinical Trials

Austin Michael Faught
Advisory Professor: David S. Followill, Ph.D.

Introduction: Commercially available treatment planning systems (TPS) may use a number of
different radiation dose calculation algorithms during the planning process. The Radiological
Physics Center (RPC), tasked with ensuring clinically comparable and consistent dose delivery
amongst institutions participating in NCI funded multi-institutional clinical trials, has traditionally
relied upon measurements to achieve this objective. As a supplement to the tools used by the
RPC, an independent dose calculation tool is needed to determine patient dose distributions in
three dimensions so as to act as a quality assurance tool for the dose calculations.

Methods: Multiple source models representing the output of Elekta 6MV and 10MV and
Varian TrueBeam Flattening Filter Free (FFF) 6MV and FFF 10MV therapeutic x-ray beams
were developed. The Monte Carlo technique, using the Dose Planning Method (DPM)
algorithm, was used in radiation dose calculations. During validation calculations were
compared to open field measurements in a water phantom. Benchmarking was a measurement
based comparison of mock treatment plans in anthropomorphic phantoms. Treatment plans
included intensity modulated radiation therapy and stereotactic body radiation therapy
techniques. Past phantom treatment plans submitted through a remote auditing program were
recalculated using the tool and compared to submitted measurement data as a test of the
models’ robustness.

Results: The average percentage of data passing a ±2%/2mm gamma criterion during
validation testing was 99.5%, 99.6%, 98.1%, and 98.1% for Elekta 6MV, 10MV, Varian
iii

TrueBeam FFF 6MV, and FFF 10MV beams, respectively. The percentage of data passing the
benchmarking evaluation criterion of ±3%/2mm was 87.4%, 89.9%, 90.1%, and 90.8% for
Elekta 6MV, Elekta 10MV, Varian TrueBeam FFF 6MV, and Varian TrueBeam FFF 10MV
beams, respectively.

Conclusions: Elekta 6MV and 10MV and Varian TrueBeam FFF 6MV and FFF 10MV multiple
source models based on dose calculations using the DPM Monte Carlo code were successfully
developed, validated, and benchmarked against measurements. A recalculation of TPS dose
from archived phantom credentialing audits was performed as a proof of concept for the
models’ utility as a quality assurance tool for use in clinical trial audits.
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Chapter 1: Introduction

1.1 Statement of Problem
The Radiological Physics Center (RPC) is one of three National Cancer Institute (NCI)
funded, quality assurance (QA) offices that provides QA auditing services to institutions
participating in NCI cooperative clinical trials. The RPC has developed several programs as a
means to efficiently provide dosimetric and QA services to the clinical trial community and to
ensure NCI that the institutions participating in clinical trials deliver comparable and consistent
radiation doses. The RPC’s QA programs are comprised of on-site evaluations and remote
auditing tools. The on-site evaluations consist of interviews of personnel that perform physical
measurements on the therapy machines, a review of quality control procedures, measurement
of basic beam dosimetry data, and a review of patient dose calculations. The remote auditing
tools are used to review patient dose calculations, measure reference beam output with
optically stimulated luminescence dosimeters (OSLD), and evaluate advanced treatment
procedures with anthropomorphic QA phantoms.

The anthropomorphic QA phantoms are

designed to test the entire treatment process beginning with imaging of the patient and
continuing through treatment planning, set-up, and delivery of the prescription dose. This is
done by comparing measurements from the phantom’s thermoluminescent dosimeters (TLD)
and radiochromic film to predicted values obtained from the institutions’ calculations performed
by the treatment planning system[1].
Measurement based comparisons historically have provided acceptable assurance
evaluating an institution’s ability to accurately deliver dose for conventional treatment
procedures. With recent advances in radiotherapy that allow for highly conformal dose
distributions and steep dose gradients through the use of multi-leaf collimators (MLC), dynamic
wedges, and advanced delivery techniques including three dimensional stereotactic
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radiosurgery and intensity modulated radiation therapy (IMRT), there is a growing concern that
the limits of measurement uncertainty are being approached[2]. As reported by the New York
Times, increased complexity in treatment modality creates the potential for devastating errors
in the administration of therapeutic radiation [3-10]. In addition, patient dose calculations in the
lung or near bony anatomy using the new treatment delivery technologies require the use of
heterogeneity correction dose algorithms that the RPC is currently not able to fully verify with its
current QA tools. The RPC has published results detailing the associated uncertainty with
TLD[11] and radiochromic film[12] as well as the results from the remote anthropomorphic
phantom audit program that present the ability of institutions to conform to prescribed treatment
plans[13-17]. These publications show a varying degree of compliance among the treatment
plans with variability among different plans generated from the same treatment planning
system (TPS). There is reason to believe that these plan variations could be from the beam
commissioning process, delivery of the treatment, and the accuracy of the dose calculation
algorithms used by the TPS[12, 18, 19]. The observed differences between institutions have
caused concern that variations and inaccuracies in the delivery of radiation therapy between
institutions could negatively impact patient safety and compromise the conclusions drawn from
NCI supported multi-institutional clinical trials. Currently the RPC has no means by which to
check the dose calculations made by the TPS for IMRT and heterogeneity corrected treatments
to catch any errors resulting from the dose calculation algorithms. In order to evaluate the
actual dosimetry and judge the accuracy of the TPS predicted dose distributions, a trusted
independent dose calculation tool is needed. This would also allow for retrospective analysis of
past clinical trials in which all dosimetry data could be normalized based on an independent
dose calculation standard.
For this reason, the RPC began the development of a multiple source model that is
executed using the Monte Carlo (MC) technique for dose calculations[20, 21]. The MC
technique is a means to numerically solve the transport equation by means of simulating the
stochastic processes using random sampling. It has been generally accepted as the most
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accurate means of radiation dose calculation[22] and is particularly useful in calculations in
which interfaces between materials along the transport path exhibit large differences in density
and/or atomic numbers[23]. The accuracy of the MC technique has been tested against
deterministic algorithms for a variety of codes including EGS4[24, 25], ITS[26, 27], MCNP[28],
and PENELOPE[29-31]. Despite its superior accuracy compared to deterministic methods, MC
based methods have not been widely implemented into the radiotherapy clinic due to the
computational intensity of the calculations[22, 23]. Recent improvements in MC code and
improvements in technology that have resulted in increased computational speed have
motivated increased consideration to treatment planning systems utilizing MC techniques[22,
32].
The improved accuracy of the MC technique is of particular significance in calculating dose
in tumors that lie near lung/air interfaces in the body [22, 33]. In these regions, tissues and air
cavities may have radiological properties that are substantially different from water. This
necessitates heterogeneity corrections for standard deterministic methods of calculating
dose[34]. Davidson et al. have documented how these correction factors may lead to
differences between measurement and calculation in heterogeneous media when using
conventional analytical dose calculation algorithms[12, 18].
The RPC’s previously developed multiple source model[35], a dose calculation tool for
Varian (Varian Medical Systems, Palo Alto, California) 6MV and 10MV photon beams, was
executed using the Dose Planning Method (DPM) code. The open source code allows for easy
modification and interfacing, making it a good choice of code to execute the MC simulations.
DPM uses standard condensed history modeling for electron transport, and is what’s known as
a mixed scheme[23]. This means that large energy transfer collisions are treated in an
analogue sense (event-by-event) and small loss collisions are approximated using the
continuous slowing down approximation (CSDA) using a restricted stopping power[22, 23].
Photon transport is handled on an interaction by interaction basis and is composed of
photoelectric absorption, Compton scattering, and pair production[23]. By altering the transport
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mechanics such that large electron transport steps may be taken, even across heterogeneous
boundaries while maintaining the necessary accuracy, the computation speed has been greatly
improved, keeping differences between DPM and other MC codes below 1.25% and statistical
uncertainty on the order of 0.2% of the maximum dose[23].
To aid in integrating the source model with the DPM code, a graphical user interface
designed to run off the Computational Environment for Radiotherapy Research (CERR)[36]
software platform was designed in the application MATLAB (MathWorks Inc., Natick, MA).
CERR was developed to create a common data structure for treatment plan databases that
would facilitate multi-institutional collaborations amongst the radiation therapy community.
Within radiotherapy treatment planning and dose calculation, the linear accelerator output
may be modeled in three primary ways. First, a complete simulation of the linear accelerator
mechanics may be done and saved to a phase space plane for further simulations in the future.
While more rigorous, this method is strongly influenced by hardware specifics that may be
difficult to ascertain or are proprietary in nature. It also requires the most memory usage of the
three methods [37-40]. Second, an analytical description of the output, based on the full
simulation, may be used in the form of a multiple source model. The multiple sources arise
from the grouping of photons based on their last interaction prior to being stored in the phase
space plane [37-44]. The final means, and method of choice for the RPC’s model, is a
measurement based multiple source model in which output is matched to standard dosimetry
data. This has the advantage of being independent of the complexities within the treatment
head[22]. Parameters to the analytical models describing the multiple sources are derived by
minimizing the difference between simulated and measured data [45-49].
Currently, the multiple source model is comprised of three analytical components describing
the output of a therapeutic megavoltage photon beam. The components correspond to the
primary source in the treatment head, an extra-focal scattering source, and a source to model
electron contamination in the beam. The analytical model is coupled to the DPM code where
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simulation of the particle transport occurs resulting in the independent dose calculation tool[20,
21].
The primary point source represents isotropically emitted photons originating from the target
inside the linac head. A second, extra-focal source is added to model scattered photons within
the linac head and is placed at a location corresponding to the flattening filter within the linac.
While only included in the Varian 10MV model done by Davidson et al., a third source
representing electron contamination may sometimes be added to the model. Studies have
suggested that this source may not be necessary for linacs of nominal energies less than or
equal to 10MV.
This project will be based on the extension of the currently developed multiple source model
for Varian megavoltage, therapeutic, linear accelerators to include linear accelerators
manufactured by Elekta (Elekta AB, Stockholm, Sweden) and Flattening Filter Free Varian
TrueBeam with nominal beam energies of 6MV and 10MV. In its current stage, the calculation
tool may be used as a generic model for Varian linacs of different models. By extending the tool
to Elekta and Flattening Filter Free Varian TrueBeam, the RPC will be able to use the tool for
most of the remaining 25% of machines used clinically. While specific models of a
manufacturer have been extensively modeled using the Monte Carlo technique[39, 50, 51],
there have been a limited number of studies exploring generic models meant to cover a range
of models by a manufacturer[52-54]. RPC measured dosimetry data suggests that a standard
dataset can match measurements from modern linear accelerators of the same nominal energy
and manufacturer[55, 56].

5

1.2 Benefits to Science
The RPC wishes to incorporate the generic model into a fully integrated calculation tool for
use in analysis of clinical trial data. This tool would allow for the accurate modeling of nearly all
megavoltage, therapeutic photon beams monitored by the RPC[55, 56] and easy importation of
treatment plan data including beam and MLC configurations and CT data representing the
calculation grid for dose calculations. This tool will have four primary uses within the RPC’s QA
program:
1) It will complement the anthropomorphic phantom program by allowing for an
additional data source in comparison of measurement data and TPS calculated
dose distributions.
2) It may act as means to provide direct comparison of retrospective patient treatment
plans from clinical trials. This would isolate the performance of the TPS dose
calculation from all other variables in the treatment process.
3) It will allow for the comparison of TPS dose calculation algorithm performance. RPC
studies[13-17] have shown that discrepancies between TPS data and measured
data from the phantom QA program can be largely dependent on beam modeling
errors, planning mistakes, and errors in phantom set up. By importing a single
treatment plan to the institution TPS for dose calculation, the performance of the
TPS calculation may be objectively compared through the use of a standard
baseline established by the calculation tool using the DPM engine.
4) Extension of the calculation tool to include a flexible source model for Elekta and
Flattening Filter Free Varian TrueBeam machines will act as a valuable quality
assurance tool that allows the RPC’s quality assurance program to test areas of the
radiation therapy treatment process previously not possible.

The new models will be developed and commissioned in a step by step process beginning
with validation against basic dosimetry data, benchmarking against phantom based
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measurements, and finally benchmarking against outside institution phantom measurements
previously submitted through the RPC’s credentialing program. A detailed explanation of the
proposed methods and issues to be resolved are contained below.

1.3 Hypothesis and Specific Aims

Hypothesis: A dose calculation quality assurance tool using the Dose Planning Method Monte
Carlo technique coupled to multiple source models of Elekta 6MV and 10MV and Varian
TrueBeam FFF 6MV and FFF 10MV beams can perform dose calculations to an accuracy of
±3% of the maximum dose and ±2mm distance to agreement for conformal radiation therapy
and intensity modulated radiation therapy in homogeneous and heterogeneous media as
determined by anthropomorphic phantom based measurements.

Specific Aim 1: Modify and extend a multiple source model dose calculation tool previously
developed for Varian linear accelerator (linac) 6MV and 10MV photon beams to include Elekta
6 MV and 10MV, and Varian TrueBeam FFF 6MV and FFF 10MV photon beams using the
same model optimization process. The dose calculation tool will be validated, and the accuracy
will be verified against depth dose data and dose profiles for field sizes up to 40 x 40 cm2.
Acceptance between the dose calculation and measured dosimetry data is ±2%/2mm distance
to agreement (DTA) for 90% of all data.

Specific Aim 2: The dose calculation tool will be benchmarked against measurements for
Elekta 6MV and 10MV and Flattening Filter Free Varian TrueBeam 6MV and 10MV photon
beams using the Radiological Physics Center’s (RPC) anthropomorphic phantoms. These
phantom measurements will include measurements for a homogeneous intensity modulated
radiation therapy (IMRT) head and neck phantom, stereotactic lung phantom, and
7

heterogeneous IMRT lung treatments. The accuracy of the dose calculation tool will be within
±3%/2mm DTA of measurements for 85% of the data tested.

Specific Aim 3: The dose calculation tool will be benchmarked against measurements
submitted by outside institutions as a part of the Radiological Physics Center’s remote auditing
program. Plans will be selected to include previously passing deliveries that will test the
robustness of the models and their ability to predict dose distributions from linear accelerators
whose dosimetry data were not used during commissioning and validation of the models.
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Chapter 2: Materials and Methods: Development, Validation, and Benchmarking
2.1 Introduction
Interest in the Monte Carlo (MC) technique as means for dose calculations has been
motivated by its superior accuracy compared to traditional, deterministic algorithms[22]. While
different codes utilizing the technique have been developed[23, 25, 28-30], all operate under a
similar idea that with known interaction probability distributions of electrons and photon
radiation may be transported with a high degree of statistical certainty. While deterministic
algorithms used by modern day treatment planning systems have been shown to perform well
in dose calculations, there have been demonstrated instances of disagreement between
calculated and measured data in conditions of heterogeneous media, small field sizes, and/or
steep dose gradients[12, 18]. Due to challenges associated with measuring a full threedimensional dose distribution in realistic clinical circumstances (e.g. within an anthropomorphic
phantom), the MC technique is an excellent way to evaluate the performance of commercial
treatment planning dose calculation algorithms.
Traditionally MC dose calculations are performed via a full simulation of the mechanics
within the linear accelerator. Depending on the dosimetric quantities of interest and the
measurement conditions, results may be highly dependent on the accuracy and completeness
of the model geometry. Out of field doses in particular rely upon more than the general beam
line components such as target, flattening filter, jaws, and multi-leaf collimator (MLC) that can
model standard in field dosimetric quantities. The execution of this type of model can be
cumbersome as the level of detail needed in modeling specific components may be considered
proprietary information by the manufacturer and as a result not readily available. Alternate
means of modeling as detailed in the American Association of Physicists in Medicine’s Task
Group Report No. 105 (TG-105)[22] have been implemented. These include a multiple source
model based on the full simulation of an accelerator in which particles are grouped based on
their points of interaction and described analytically. A third method is a measurement based
9

multiple source model in which an analytical description of particles is generated based on
minimizing differences between resultant calculated data and measured data.
Another obstacle to the wide spread implementation of MC dose calculations has been its
computational intensity. Within a clinical environment, it is not always practical to wait for a
dose calculation with sufficient statistical certainty. Advances in computer technology and the
use of GPU based calculations have cut the required time down substantially and renewed
interest in clinical MC calculations. Additionally alternate approaches of simplifying the MC
transport have been developed to cut down on calculation time [23, 57, 58].
Originally developed and commissioned for field sizes up to 10 x 10 cm2 by Joseph Deasy
and his research group out of Washington University in St. Louis[20], the RPC has documented
its modifications and development of an independent, dose calculation, quality assurance tool
for Varian linear accelerators of nominal photon beam energies 6MV and 10MV up to field
sizes of 40 x 40 cm2 including fields modulated by MLCs[21, 35]. This tool was designed with a
generic model of Varian megavoltage, therapeutic, x-ray beams such that individual beam
models would not be needed for every beam monitored by the RPC. In short, the model was a
measurement-driven multiple source model consisting of analytical descriptions of a primary
point source, an extra-focal disk source, and an electron contamination source. The model was
shown to accurately account for off-axis effects, namely increased fluence and decreased
mean energy, resulting from the flattening filter.
It’s estimated that the current dose calculation tool covers approximately 75% of the beams
monitored by the RPC. Notable exclusions are Elekta and Siemens manufactured linear
accelerators and linear accelerators operating in flattening-filter-free mode, notably the Varian
TrueBeam accelerator. Chapter 3 reports on the development of Elekta 6MV and 10MV
therapeutic x-ray beam models to be included in the dose calculation tool, and Chapter 4
reports on the inclusion of a Varian TrueBeam linear accelerator operating in flattening filter
free mode. Validation of the models was tested by comparing ion chamber measurements in a
water phantom for depth dose data and dose profiles for square field sizes. Benchmarking was
10

performed using the RPC’s anthropomorphic phantoms that contain thermo-luminescent
dosimeters (TLD) and radiochromic film. In this stage the entire model was evaluated in
clinically realistic scenarios including both homogenous and heterogeneous media with highly
modulated and small fields.

2.2 Source Model
2.2.1 Hardware
Dose calculations were performed on a Hewlett Packard ProLiant DL585 G5 3.2 GHz server
with four AMD Opteron™ processors with four core CPU’s and 32 GB of RAM (HewlettPackard Company, Palo Alto, CA) and a Hewlett Packard ProLiant DL380 G8 server with two
Xeon® CPU E5-2602 with six core CPU’s (Hewlett-Packard Company, Palo Alto, CA).

2.2.2 Software
Calculations and analysis were performed with MATLAB (MathWorks Inc., Natick, MA) and
the use of the Computational Environment for Radiotherapy Research (CERR)[36]. Execution
of the MC code was done using the Dose Planning Method (DPM)[23] utilizing low energy
electron and photon cutoffs of 200 keV and 50 keV, respectively. To cut down on calculation
time, each simulation was broken into smaller batches and individual beams such that
calculations were allocated to individual processors using MATLAB’s Parallel Processing
Toolbox.

2.2.3 Source Model Commissioning
The commissioning of a source model was completed in two steps. The first was based on
central axis depth dose data from a 10 x 10 cm2 field size. Separate dose calculations were
performed for mono-energetic bins of 0.25 MeV increments through the nominal energy range
11

of the beam for both primary and extra-focal sources. The relative weight between each of the
bins was adjusted during an optimization process to match measured percent depth dose data
(PDD).
Optimization involved the adjustment of seven unique parameters used to describe the
shape and position of the primary and extra-focal energy spectra, relative fluence of the
primary and extra-focal sources, electron contamination contribution, and a parameter used to
model the volume average blurring from the use of an ion chamber in collecting measurement
data. The parameters used to describe the energy spectra shape were based on the product of
a Fatigue-Life function and Fermi Distribution, shown below in Equation 2.1, and referred to as
a Fatigue Fermi Distribution by Davidson et. al[20, 21, 35].
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(2.1)

)

Such that E>µ; γ,β>0

In the above equation, E is the photon energy, EF the cut-off energy, and µ, β, and γ shape the
photon spectrum. This function was chosen for the Elekta model to 1) be consistent with the
spectra modeling used for the Varian models by Davidson et al. [20, 21, 35] and 2) its ability to
fit the photon spectra from numerous linac manufacturers determined from the Monte Carlo
code BEAM and studied by Sheikh-Bagheri and Rogers[59] without being overly
parameterized.
The distribution matched exactly with the Varian model with the exception that the locations
of the extra-focal source and electron contamination source were moved to be consistent with
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the location of the flattening filter within Elekta machines. Briefly, these distributions consisted
of a primary point source corresponding to photons created within the target, an exponential
disk source[60] used to model photons originating from scatter events in the linac head
(primary collimator, jaws, MLC, flattening filter, etc.) and a uniformly distributed, circular
electron contamination source. The energy distribution for the extra-focal source is modeled by
the same distribution as the primary source, Equation 2.1, but scaled down in the relative
fluence and maximum energy. The electron contamination source has an energy spectrum
modeled by an exponential function described by Fippel et al. [53] for Elekta and Siemens
linacs. Its relative contribution was determined during the optimization process and was
included in both Elekta 6MV and 10MV and TrueBeam FFF 6MV and FFF 10MV models,
contrary to the Varian model in which Davidson et al.[35] chose to exclude it for the 6MV
model.
The output of the MC simulation is in units of energy per source particle. To convert the
resultant calculations into the more useful units of dose per monitor unit (MU), the output was
scaled by a constant factor to match the dose at a depth of dmax for the 10 x 10 cm2
measurements and calculations.
The second step of the commissioning process is based on measured data from a 40 x 40
cm2 field size, and is executed with the intention of modeling off-axis effects such as increased
off-axis fluence and decreased mean energy off-axis, collectively contributing to the Horn
Effect. Using the optimized spectra from the first step and an off-axis correction for half-value
layer (HVL) formulated by Tailor et al. [61] (Elekta models) and Georg et al.[62] (TrueBeam
FFF Models) and implemented without change, calculations were run for 1600 1 x 1cm2
beamlets, making up an open 40 x 40 cm2 field. Each beamlet’s contribution to the total dose
was adjusted based on a piecewise linear function such that the calculated dose profiles were
matched to measured dose profiles at a depth of dmax.
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2.2.4 Machine Output Correction
Similar to the output correction used by Davidson et al.[35], and documented in the
literature[63, 64], a second order hyperbolic equation was used to correct for machine output
as a function of field size for the Elekta models. This was done by a least squares fit of the ratio
of calculated and measured output factors as a function of field size. The correction factor was
then applied to the entire three-dimensional (3D) dose matrix after calculation. No output
correction was needed for the Varian TrueBeam FFF models.

2.2.5 Fluence Map
A projected fluence map at isocenter was formed with dimensions determined by the jaw
settings. This map was divided into 1 x 1 mm2 fluence segments with the option of a finer 0.5 x
0.5 mm2 at the cost of increased computation time and memory. The fluence through each
fluence segment was determined from MLC position pulled from the DICOM plan file for each
plan segment, the transmission through the MLC leaves, transmission through the rounded leaf
ends, and the leakage between adjacent leaves. Each group of fluence segments exposed to
the primary source during the plan segment were assigned a fluence based on the number of
monitor units per plan segment. The transmission through the MLC assigned additional fluence
to the fluence segments as a percentage of the monitor units in an amount that varied along
the leaf length with the least amount being at the rounded tips of the leaves. A piecewise linear
function was used to weight the fluence in this region to model the rounded tip. The fluence
segments that this function was applied to corresponded to the projected width of the leaves at
isocenter and an effective tip length of 5mm. This resulted in a more effective modeling of the
penumbra caused by the shape of the leaves. Interleaf leakage was modeled by assigning
additional fluence, expressed as a percentage of the monitor units, to the fluence segments.
This was done along the fluence segments alongside the leaves in 1mm wide region with
length corresponding to the leaf positions. A final, composite fluence map was calculated by
summing the 1 x 1 mm2 fluence segments from all beam segments determined in the treatment
14

plan. The DPM calculation was then run by segmenting the fluence map into beamlets of
similar monitor units.

2.2.6 Primary Source Size
The primary source corresponding to photons created within the target of the linear
accelerator head was treated as a point. In reality, it is known that this is finite in size and
ranges, dependent on linear accelerator manufacturer, from 0.5mm to 3.4mm in full width at
half the maximum[65]. The finite size of the source results in an exaggerated penumbra,
dependent on source size, distance from the collimator jaws, and distance between the
collimator jaws and point of measurement, referred to as the geometric penumbra. To mimic
this effect in a point source model, an offset in the MLC leaf positions was implemented in the
amount of 0.4mm. This remains unchanged from the previously developed Varian model[20,
21, 35].

2.2.7 Electron Contamination Contribution Versus Field Size
Similar to the overall output correction discussed in 2.2.1.4, a field size dependent output
correction was used for the electron contamination contribution in the Elekta models. This too
was a second order hyperbolic equation. This correction was necessary to model the increased
head scatter contribution with relation to the field size which affects the build-up region of the
depth dose curves and the depth of maximum dose. No field size dependent correction factor
was used for the Varian TrueBeam FFF models.

2.3 Validation Testing
Validation of the Elekta source models was done through a comparison of calculated
dosimetry values to basic, measured beam data. Specifically that data consisted of depth dose
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curves and dose profiles at depths of 1.6cm (dmax), 5.0cm, 10.0cm, and 20.0cm for the 6MV
model and 2.0cm (dmax), 5.0cm, 10.0cm, 20.0cm, and 25.0cm for the 10MV model. These
comparisons were done for field sizes of 3 x 3 cm2, 5 x 5 cm2, 10 x 10 cm2, 15 x 15 cm2, 20 x
20 cm2, and 30 x 30 cm2. Measurements were performed in a water phantom and calculations
were done in a simulated 50 x 50 x 50 cm3 water phantom.
Validation of the Varian TrueBeam FFF 6MV and FFF 10MV models was done through a
comparison of calculated dosimetry values to basic, measured beam data. Data consisted of
depth dose curves and dose profiles at depths of 1.5cm (dmax), 5.0cm, 10.0cm, 20.0cm and
30.0cm for the FFF 6MV model and 2.4cm (dmax), 5.0cm, 10.0cm, 20.0cm, and 30.0cm for the
FFF 10MV model. These comparisons were done for field sizes of 3 x 3 cm2, 4 x 4 cm2, 6 x 6
cm2, 8 x 8 cm2, 10 x 10 cm2, 20 x 20 cm2, 30 x 30 cm2, and 40 x 40 cm2. Measurements were
performed in a water phantom and calculations were done in a simulated 50 x 50 x 50 cm3
water phantom.
The calculated data was extracted from the 3D dose matrix relative to the surface of the
virtual water phantom, as defined by the skin contour. The resolution of the calculated data was
0.2cm in the depth direction, defined as ‘y’ in the CT data set, 0.2cm in the in-plane direction,
defined as ‘x’ in the CT data set, and 0.3cm in the cross-plane direction, defined as ‘z’ in the CT
data set.
The measured data was the same data used for the commissioning of the clinical treatment
planning system and were performed using a Wellhöfer CC13 ionization chamber (internal
volume of 0.13cc) manufactured by CNMC (Best Medical, Nashville TN) for the Elekta
measurements and a PTW 31010 ionization chamber (internal volume of .125cc) (PTW,
Freiburg, Germany) for the Varian TrueBeam FFF measurements. To account for volume
averaging effects of the ionization chamber that exaggerate the penumbra, a Gaussian
convolution was applied to all dose profiles for comparison of measured and calculated data.
The standard deviation of the kernel applied in the convolution was one of the seven
parameters defined during model optimization.
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Agreement between measured and calculated data was evaluated using gamma analysis
with a criterion of ±2% of the maximum dose and ±2mm distance to agreement. For dose
profile comparison, the analysis was performed out to an off-axis distance corresponding to 5%
of the maximum central axis dose.
2.4 Anthropomorphic Phantoms
The RPC’s anthropomorphic head and neck phantom, shown in Figure 2.1, consists of a
hollow, plastic head that may be filled with water to mimic radiological properties similar to
tissue. Contained within the hollow shell is a removable insert constructed of polystyrene with
solid water structures representing two separate targets and a single organ at risk (OAR). Also
contained in the insert is space for the placement of radiochromic film (Gafchromic EBT2,
Ashland Inc., Covington, KY) in the axial and sagittal directions and thermoluminescent
dosimeter (TLD) capsules (TLD-100 capsules, Radiation Detection Company, Gilroy, CA). The
orientation of the insert within the shell, and the targets and OAR within the insert, are such that
the phantom presents a clinically realistic challenge. For detailed specifications about the
phantom design, the reader is referred to an article published by Molineu et al.[66].
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Figure 2.1: The anthropomorphic, hollow, plastic shell to the RPC’s head and neck phantom
with the polystyrene insert removed and opened. The polystyrene insert in the RPC’s head and
neck phantom is opened up to reveal a transverse, cross sectional view. The insert contains a
primary PTV, secondary PTV, and critical structure made of solid water that may be
distinguished from the insert in a CT scan for treatment planning purposes. Also pictured are
the holes to house the thermoluminescent dosimeters (TLD) for absolute dosimetry. The
orthogonal slits intersecting in the primary PTV are for sagittal an coronal films while an axial
film may be placed between the two halves to the insert shown in this cross sectional image.

The planning criteria established by the RPC and RTOG protocol H-002 for credentialed
institutions will be used in the benchmarking study. It is as follows:
1) 6.6 Gy delivered to 95% of the primary PTV
2) 5.4 Gy delivered to 95% of the secondary PTV
3) Less than 1% of the PTVs may receive less than 93% of the prescription dose
4) OAR is to receive a dose less than 4.5 Gy
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5) Normal tissue dose must be held under 110% of the prescription dose

The heterogeneous, anthropomorphic thorax phantom designed by the RPC, shown in
Figure 2.2, consists of a hollow PVC shell filled by water that contains structures of varying
materials representative of human anatomy including a heart (nylon), spine (PBT-polyester),
lungs (compressed cork), and a lung tumor (polystyrene). To simulate the slope of a human
chest, the anterior surface of the outer shell is slightly angled. At a position consistent with the
left lung, the phantom contains a removable imaging/dosimetry insert. Within the dosimetry
insert is space for TLD capsules and radiochromic film in the axial, sagittal, and coronal planes.
A detailed description of the phantom specifications can be found in the literature[67].

TLD Rods

Figure 2.2: The outer shell of the RPC’s thorax phantom with the lung insert partially removed.
Within the insert are slits for the placement of radiochromic film and holes for TLD. Rods
containing TLD capsules are also inserted into the shell for point dose measurements
corresponding to the location of the spinal cord and heart, the representative critical structures
for this treatment. Also pictured (right) is the disassembled lung insert with locations for
radiochromic film and TLD and the removed TLD rods (bottom left).
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Planning criteria decided upon by the RPC and RTOG protocol 0236 to be used in the
benchmarking study are as follows:
1) 66 Gy to 95% of the PTV (clinically delivered in 33 fractions)
2) Less than 45 Gy to the spinal cord
3) Less than 20 Gy to 40% of the lung
4) Less than 40 Gy to the entire heart
5) Less than 50 Gy to 50% of the heart

The dosimeters contained within the phantom are all specified at doses less than the clinical
constraints given above. Therefore all plans will be scaled down by a constant factor of 11 and
delivered in a single fraction[35, 67].

2.5 Benchmark Testing
The benchmarking of the validated source model was designed to be done in a step by step
process with increasingly difficult treatment planning and computational challenges including
heterogeneous media, small field sizes, and highly modulated treatment plans. The RPC’s
anthropomorphic head and neck phantom was used in creating, delivering, and comparing to
calculation a highly modulated, nine co-planar beam, IMRT plan to the homogenous phantom.
Next benchmarking was done on the RPC’s heterogeneous lung phantom with first a nine coplanar beam stereotactic body radiotherapy (SBRT) plan followed by a six co-planar, IMRT
plan for 6MV and 10MV models, respectively. All treatment plans were designed to meet the
credentialing criteria established by the RTOG and delivered three times to evaluate the
repeatability.
The accuracy of the calculations was then assessed by comparing point doses from TLD
measurements, and dose profiles and 2D gamma comparisons from film measurements.
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2.5.1 Point Dose Comparisons
Point dose comparisons were made between calculated doses and measured TLD doses of
the target and critical structures. The measured doses were determined from the small volume
of TLD powder contained in the TLD capsule, and the calculated values were determined from
a corresponding contour of the TLD in the CT scan.

2.5.2 Dose Profile Comparisons
Dose profiles along the three primary axes and passing through the target volume were
used as a qualitative evaluation of agreement between the source model and measurements
performed in the phantoms. Anterior posterior (AP) and left-right (LR) profiles were extracted
from the axial films and profiles along the superior/inferior (SI) direction were taken from the
sagittal films. Due to the sagittal films being bisected by the axial film plane, a discontinuity in
the center of the measured dose profile exists where the two sagittal films meet. Measured
dose in this region should be ignored as a result. While quantitative information exists in the
profile comparisons, the analysis was restricted to qualitative evaluation of the models’ ability to
predict complex dose distributions. The quantitative assessment of distance to agreement was
evaluated in the gamma analysis detailed in section 2.5.3.

2.5.3 Gamma Map Comparisons
Two dimensional dose distributions were evaluated using the gamma index technique[68]
as a means of evaluating the project hypothesis. Agreement between calculated and measured
dose was evaluated in the film planes intersecting the phantom target to a criterion of ±3% of
the target TLD dose and ±2mm distance to agreement.
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Exclusion of selected regions of the film were performed in areas in which discontinuities or
alterations of the film were made to allow for proper assembly of the dosimetry tools. These
included cut out regions of film along the central AP axis and central lateral axis of the sagittal
and coronal films in the thorax phantom that allow for arrangement of the film along a shared
axis, a small cutout on the right, postero-lateral corner of the axial film for the head and neck
phantom to allow for proper placement of the film, and a cutout in the sagittal film plane to allow
for placement of the critical structure TLD. An example from the sagittal film plane of head and
neck phantom is included in Figure 2.3.

Figure 2.3: Exclusion mask used in the evaluation of the sagittal film from the IMRT head and
neck phantom. The exclusion areas are indicated by red lines and correspond to discontinuities
between the superior and inferior film pieces, a cutout for the placement of the OAR TLD, and
the pin pricks used to localize the film within the phantom insert.
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As a representative example of the area of the film that was evaluated, Figure 2.4 shows
the evaluated region as dose cloud overlaid on the CT scan for the axial plane of the head and
neck and lung phantoms, respectively.

Figure 2.4: Region of interest evaluated using gamma analysis for the axial plane of the IMRT
head and neck phantom (left) and lung phantom (right) is shown with the dose cloud from a
treatment plan overlaid on the CT scan. For delineation of specific structures in the CT scan in
each phantom see Figures 2.5 and 2.6.

2.5.4 Treatment Plans
2.5.4.1 Elekta Benchmarking
Treatment plans for the benchmarking of the Elekta 6MV and 10MV models were developed
using the Pinnacle treatment planning system version 9.6 (Philips Medical Systems, Andover,
MA). Evaluation of the dose constraints during planning were performed using Pinnacle’s
collapsed cone convolution algorithm.
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The primary goal in developing the treatment plans was to increasingly challenge the dose
calculation tool in clinically relevant ways. Because of this, there were some exceptions made
to the planning criteria established by the RTOG and RPC in order to increase the complexity
of the plan. For example, the planning criteria for the lung phantom can be met quite easily
without the use of highly modulated fields. This however would not provide a satisfactory test of
modulated fields in a heterogeneous medium for the calculation tool. As a result, modulation
was forced in the plan at the expense of increasing the whole lung dose to a level that would
otherwise be unacceptable in an institutional audit.
For the head and neck phantom, 95% of the primary PTV, constrained to the identified GTV
in the CT scan as shown in Figure 2.5 with the OAR contours, was to receive at least 6.6Gy.
The percentage that actually achieved this constraint was 87.4% and 90.4% for the 6MV and
10MV plans, respectively. However the volumes receiving 6.5Gy were 98.5% and 95.9% for
the respective plans. The secondary PTV was to receive 5.4Gy to 95% of the volume when in
actuality the plans achieved 85.7% and 98.2%, respectively. For the 6MV plan 99.9% of the
secondary PTV received a dose of 5.3Gy, 10cGy less than the actual requirement. The OAR
dose was to be kept below 4.5Gy for 100% of the volume. In the actual treatment plans 0.1%
and 0.6% received a dose of 4.5Gy. The maximum dose to normal tissue was 7.22Gy and
7.45Gy, respectively. The total number of segments in the plan was 107 for both 6MV and
10MV plans. While the planning criteria were not strictly met, it was decided that the levels
achieved provided a clinically realistic enough of a plan to still test the calculation tool’s ability
to model modulated fields in the homogenous phantom.
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Figure 2.5: Axial (top), sagittal (bottom left), and coronal (bottom right) views of the CT scan of
the head and neck phantom. Contours are the primary PTV (red), secondary PTV (green), and
critical structure, the cord, (blue). The dark circles within the contours are the regions where the
TLD are placed within the phantom and the location for point dose comparisons between
measurement and calculation.
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The planning criteria for the SBRT plans on the thorax phantom were met fully. Briefly,
97.8% and 99.4% of the PTV, defined as an expansion of 0.5cm of the GTV in the axial plane
and 1.0cm expansion in the longitudinal plane and shown with the OAR in Figure 2.6, received
the prescription dose for the 6MV and 10MV plans, respectively, and the maximum cord dose
was kept to 2.0Gy and 2.2Gy, well below the 5.0Gy limit, for the respective plans. The dose to
the heart was below 1.4Gy and 1.6Gy for the two plans. Whole lung dose was kept below
2.0Gy for 11.7% and 13.1% of the volume for each of the plans.
For the IMRT plans on the lung phantom 97.0% and 96.1% of the PTV, defined in the same
way as the SBRT plan above, met prescription for the 6MV and 10MV plans, respectively.
Maximum dose to the cord was held at 1.8Gy for both plans, and the maximum heart dose was
3.2Gy for 6MV and 10MV plans. The volume of the whole lung exceeding 2.0Gy was 47.8%
and 47.4%, respectively, thus exceeding the desired maximum volume of 37%. Again, this was
determined necessary in order to force the level of modulation desired for evaluation the model.
The total number of segments in each plan were 45 and 44 for 6MV and 10MV plans,
respectively.
Monte Carlo calculation resolution was matched to the CT voxel size. For the head and
neck treatment plans this was 0.518 x 0.518 x 1.25 mm3, and for the lung treatment plans it
was 1.27 x 1.27 x 1.25 mm3.
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Figure 2.6: Axial (top), sagittal (bottom left), and coronal (bottom right) views of the CT scan of
the thorax phantom. Contours are the PTV (green), heart (red), and the cord (blue). The dark
circles within the contours are the regions where the TLD are placed within the phantom and
the location for point dose comparisons between measurement and calculation.
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2.5.4.2 Varian TrueBeam FFF Benchmarking
Treatment plans for the benchmarking of the Varian TrueBeam FFF 6 and FFF 10MV
models were developed using the Eclipse treatment planning system version 11.0 (Varian
Medical Systems, Palo Alto, CA). Evaluation of the dose constraints during planning were
performed using Eclipse’s analytical anisotropic algorithm (AAA).
For the head and neck phantom, 95% of the primary PTV, constrained to the identified GTV
in the CT scan as shown in Figure 2.3 with the OAR contours, was to receive at least 6.6Gy.
The percentage that actually achieved this constraint was 95.5% and 94.6% for the 6MV and
10MV plans, respectively. However the volume receiving 6.5Gy was 99.8% for the 10MV plan.
The secondary PTV was to receive 5.4Gy to 95% of the volume when in actuality the plans
achieved 98.2% and 94.1%, respectively. For the 10MV plan 99.3% of the secondary PTV
received a dose of 5.3Gy, 10cGy less than the actual requirement. The OAR dose was to be
kept below 4.5Gy for 100% of the volume. This was achieved in both plans and maximum
doses were 4.1Gy and 3.9Gy, respectively. The maximum dose to normal tissue was 6.97Gy
and 6.93Gy respectively. The total number of segments in each plan was 134 and 136 for 6MV
and 10MV plans, respectively. While the planning criteria were not strictly met, it was decided
that the levels achieved provided a clinically realistic enough of a plan to still test the calculation
tool’s ability to model modulated fields in the homogenous phantom.
The achieved planning criteria for the SBRT plans on the thorax phantom were as
prescribed with the exception of a small reduction in coverage of the PTV. Briefly, 93.8% and
93.4% of the PTV, defined as an expansion of 0.5cm of the GTV in the axial plane and 1.0cm
expansion in the longitudinal plane and shown with the OAR in Figure 2.4, received the
prescription dose for the 6MV and 10MV plans, respectively, and the maximum cord dose was
kept to 2.0Gy and 1.8Gy, well below the 5.0Gy limit, for the respective plans. The dose to the
heart was below 2.4Gy and 2.2Gy for the two plans. Whole lung dose was kept below 2.0Gy for
7.3% and 7.8% of the volume for each of the plans. Despite the small coverage discrepancy
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between achieved and prescribed criteria, the plan was still judged to be an adequate test of
the models’ performance in heterogeneous media without field modulation.
For the IMRT plans on the lung phantom 93.0% and 93.1% of the PTV, defined in the same
way as the SBRT plan above. Maximum dose to the cord was held at 0.69Gy for both plans
and the maximum heart dose was 1.2Gy for both plans. The volume of the whole lung
exceeding 2.0Gy was 11.4% and 12.0%, respectively. The drop in coverage to the PTV for
both plans was judged to be a result of placing the beams at purposefully challenging angles to
increase modulation of the plan. For the purpose of testing the models’ performance, this was
determined to be an acceptable sacrifice. The total number of segments in the plans were 63
and 64 for 6MV and 10MV plans, respectively.
Calculation resolution was matched to the CT voxel size. For the head and neck treatment
plans this was 0.68 x 0.68 x 3.00 mm3, and for the lung treatment plans it was 0.977 x 0.977 x
3.00 mm3.

29

Chapter 3: Results and Discussion: Elekta 6MV and 10MV
3.1 Source Model
3.1.1 Source Model Commissioning Parameters
The seven optimized parameters, determined in commissioning, that describe the photon
energy spectra, fluence contributions, and volume averaging of the ion chamber leading to an
exaggerated penumbra for dose profiles are reported in Table 3.1 for the Elekta 6MV and
10MV models. The first three parameters, γ, μ, and β describe the spectrum shape, peak
energy location, and relative scale respectively.
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Parameter
Fatigue-Life distribution shape parameter, γ
Fatigue-Life distribution location parameter, μ
Fatigue-Life distribution scale parameter, β

Value Elekta 6MV

Value Elekta 10MV

1.79

1.15

-0.0163

-0.0165

3.69

3.95

1.71

3.10

0.1101

0.1901

0.002

0.005

1.8

1.8

Primary spectrum to extra-focal spectrum reduction
factor
Extra-focal fluence relative to the primary fluence
Electron Contamination contribution (relative to the
primary photon contribution)
Standard deviation of Gaussian used to convolve the
MC dose profile to match the measured dose profile
during validation (in mm)

Table 3.1: Optimized parameters for the source models as determined during the initial
commissioning of the models. The first three parameters describe the shape and location of the
spectra. The fourth through sixth parameters relate the relative contribution and energy scale of
the three sources, and the final parameter is the standard deviation of the Gaussian kernel
convolved with the calculated dose profiles to mimic the volume averaging effect of an ion
chamber at the penumbra of dose profiles.

A comparison of the 6MV spectrum from the optimization process and those from the widely
accepted BEAM code[59] for simulating radiation transport in linear accelerators is show in
Figure 3.1. In Figure 2.6 a comparison of the Elekta 10MV spectrum to the Varian 10MV
spectrum from Davidson et. al[35] is shown. While not an exact match for either the 6MV or
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10MV models, the results from validation indicate that it is an adequate description of the
photon beam. The extra-focal source was scaled in energy by a factor of 1.71 and 3.10 for 6MV
and 10MV models, respectively. Their fluences, relative to the primary point source in a 10 x 10
cm2 open field, were found to be 11.01% and 19.01% for 6MV and 10MV models, respectively.
The electron contamination sources, while small at 0.2% and 0.5% respectively, were still
included in the source model, unlike the Varian 6MV model[20, 21, 35]. For the comparison of
the dose profiles, a Gaussian kernel of standard deviation 1.8mm was convolved with the
calculated data to model the volume averaging effect of an ion chamber measurement.
1.20E-04

Photons (normalized to literature)

1.00E-04

8.00E-05
Eleka 6MV- Sheikh-Bagheri
and Rogers
Elekta 6MV - Faught

6.00E-05

Varian 6MV - Davidson
4.00E-05

2.00E-05

0.00E+00
0

1

2

3

4

5

6

7

8

9

Energy (MeV)

Figure 3.1: Comparison of commissioned Elekta 6MV source model spectrum with the results
from BEAM (Sheikh-Bagheri and Rogers) and Davidson et. al.
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Figure 3.2: Comparison of commissioned Elekta 10MV source model spectrum with the results
from Davidson et. al.

The results to the second step of the commissioning process in which the off-axis fluence
was modeled by a piecewise linear function of the cosine of the off-axis angle are shown in
Table 3.2. The off-axis energy correction was implemented from Tailor et al. [61] without
change.
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Fluence Weight (Relative to CAX)

Fluence Weight (Relative to CAX)

Elekta 6MV Model

Elekta 10 MV Model

1.00000

1.0000

1.0000

0.99970

1.0390

1.0310

0.99789

1.0488

1.0620

0.99728

1.0880

1.0980

0.99518

1.1251

1.1300

0.99250

1.1687

1.1700

0.98926

1.2143

1.2000

0.98546

1.2245

1.2200

0.98113

1.2619

1.2300

0.97630

1.2933

1.2800

0.97098

1.3193

1.3000

0.96277

1.3528

1.3200

Cosine (Off-axis Angle)

Table 3.2: Optimized coefficients to a piece-wise linear function used to describe the increase
in off-axis fluence of Elekta 6MV and 10MV models. Fluence weighting values are reported with
respect to the dose measured at the central axis (CAX) for the 40 x 40 cm2 field size dose
profile at a depth of dmax.

After completing the second step of the commissioning process, the scaling factor used to
convert the Monte Carlo output from energy per particle to cGy per MU was determined from
the dose at dmax along the central axis for a 10 x 10 cm2 field size. These values were 25.17
and 15.92 for the 6MV and 10MV models, respectively. This factor will be applied to all
subsequent dose calculations for the corresponding linac/energy models.
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3.1.2 Fluence Map, Primary Source Size, and Machine Output Correction
Fluence map generation is a process that is unique to the treatment plan, patient, phantom,
or open field delivery, and beam energy. The MLC positions for each segment weight the
fluence by assuming 1% transmission through the leaves and an additional 1% as interleaf
leakage. The transmission and the leakage percentages were the same for 6MV and 10MV
models.
Because the source model includes a point source representing photons created within the
target and not a finite source size, an offset of the MLC, xpen, of 0.4mm was necessary. This
was the same offset used in the Varian model[20, 21, 35] and because the literature has
suggested its size is nearly fixed for different nominal energies from the same
manufacturer[69], it was left constant for both 6MV and 10MV models.
An empirically determined field size dependent output correction was implemented in
addition to the normal output factor due to the models inability to fully model field size
dependent scatter conditions. Each model, Elekta 6MV (equation 3.1) and 10MV (equation
3.2), had its own correction implemented.

Elekta 6MV Output Correction
(3.1)

Elekta 10MV Output Correction
(3.2)

In the above equations, y is the output correction and x is the field size. Graphs of the
measured and uncorrected and corrected data are shown below in Figure 3.3 and Figure 3.4.
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Output Correction of Elekta 6MV Multiple Source
Model
Output at Dmax (cGy/MU)
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Figure 3.3: Output at a depth of 1.6cm for the measured data (blue circles), calculated data
without the hyperbolic correction (red star), and the calculated data with the hyperbolic
correction (green x) for the Elekta 6MV source model.

Output Correction of Elekta 10MV Multiple
Source Model
Output at Dmax (cGy/MU)
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Figure 3.4: Output at a depth of 2.0cm for the measured data (blue circles), calculated data
without the hyperbolic correction (red star), and the calculated data with the hyperbolic
correction (green triangle) for the Elekta 10MV source model.
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3.2 Validation Testing
3.2.1 Uncertainty
The uncertainty in the ion chamber measurements was estimated at 1.6% (one standard
deviation) to match that reported in the literature[70]. The standard error of the mean in the
dose calculations was calculated to be no more than 2.5% using the batch method described in
AAPM Task Group Report No. 105[22].

3.2.2 Depth Dose Data
The comparison between measured and calculated depth dose data for the Elekta 6MV and
10MV models was performed for field sizes ranging from 3 x 3 cm 2 to 30 x 30 cm2. Gamma
analysis agreement using a ±2%/2mm criterion is summarized in Table 2.3. The percentage of
data passing the criterion for every field size at every depth is reported in the Appendix
(Chapter 6). For a graphical comparison between depth dose data of all field sizes please see
the Appendix (Chapter 6). As representative summary the smallest (3 x 3 cm 2), nominal (10 x
10 cm2), and largest (30 x 30 cm2) field sizes are shown for the Elekta 6MV model in Figures
3.5, 3.6, and 3.7, respectively. The same field sizes are shown for the Elekta 10MV model in
Figure 3.8, 3.9, and 3.10, respectively.
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Validation Results –Depth Dose Data
% Pixels Passing
Field Size (cm2)
Elekta 6MV Model

Elekta 10MV Model

3x3

99.4

99.4

5x5

99.4

99.4

10 x 10

100.0

99.4

15 x 15

100.0

100.0

20 x 20

99.4

100.0

30 x 30

99.4

100.0

Table 3.3: Gamma comparison agreement for Elekta 6MV and 10MV models using a
±2%/2mm criterion for measured and calculated depth dose data

Figure 3.5: Calculated (blue ‘x’) and measured (red line) depth dose curves for an Elekta 6MV
beam for a 3 x 3 cm 2 field size. Gamma agreement (red circles) for each point is also
displayed along with any points (red star) at which a failure to meet the ±2%/2mm criterion.

38

Figure 3.6: Calculated (blue ‘x’) and measured (red line) depth dose curves for an Elekta 6MV
beam for a 10 x 10 cm2 field size. Gamma agreement (red circles) for each point is also
displayed. There were no failures for this field size and as a result no failure points marked.

Figure 3.7: Calculated (blue ‘x’) and measured (red line) depth dose curves for an Elekta 6MV
beam for a 30 x 30 cm2 field size. Gamma agreement (red circles) for each point is also
displayed along with any points (red star) at which a failure to meet the ±2%/2mm criterion.
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Figure 3.8: Calculated (blue ‘x’) and measured (red line) depth dose curves for an Elekta
10MV beam for a 3 x 3 cm 2 field size. Gamma agreement (red circles) for each point is also
displayed along with any points (red star) at which a failure to meet the ±2%/2mm criterion.

Figure 3.9: Calculated (blue ‘x’) and measured (red line) depth dose curves for an Elekta
10MV beam for a 10 x 10 cm2 field size. Gamma agreement (red circles) for each point is also
displayed along with any points (red star) at which a failure to meet the ±2%/2mm criterion.
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Figure 3.10: Calculated (blue ‘x’) and measured (red line) depth dose curves for an Elekta
10MV beam for a 30 x 30 cm2 field size. Gamma agreement (red circles) for each point is also
displayed along with any points (red star) at which a failure to meet the ±2%/2mm criterion.

3.2.3 Dose Profiles
A comparison of calculated dose profiles to measurements was performed for both Elekta
6MV and 10MV models at depths of dmax, 5cm, 10cm, and 20cm for field sizes ranging from 3 x
3 cm 2 to 30 x 30 cm2. An additional comparison at depths of 25cm was performed for the
Elekta 10MV model. Gamma analysis with ±2%/2mm criteria was used as the means of
comparison and is summarized in Table 3.4. The percentages of pixels passing for each profile
compared are reported in the Appendix (Chapter 6) along with graphs of each comparison. As
a representative summary the smallest (3 x 3 cm 2), nominal (10 x 10 cm2), and largest (30 x 30
cm2) field sizes are shown for the Elekta 6MV model in Figures 3.11, 3.12, and 3.13,
respectively. The same field sizes are shown for the Elekta 10MV model in Figure 3.14, 3.15,
and 3.16, respectively.
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As can be seen in Figures 3.11 through 3.16, comparisons were performed on both in-plane
and cross-plane profiles. The Monte Carlo model however assumes an equal distance from the
target for the x-jaws and y-jaws resulting in identical calculated dose profiles for in-plane and
cross-plane. As a result, the overlapping calculated data appears as a single profile in the
comparisons. The Appendix reports the agreement along both directions, and based on the
observed agreement of these results it was decided the assumption of the model was
reasonable.

Figure 3.11: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta
6MV beam at a field size of 3 x 3 cm 2.
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Figure 3.12: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta
6MV beam at a field size of 10 x 10 cm2.

Figure 3.13: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta
6MV beam at a field size of 30 x 30 cm2.
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Figure 3.14: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta
10MV beam at a field size of 3 x 3 cm 2.

Figure 3.15: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta
10MV beam at a field size of 10 x 10 cm2.
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Figure 3.16: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta
10MV beam at a field size of 30 x 30 cm2.

Agreement between calculated and measured profile data was assessed using the gamma
technique with an evaluation criterion of ±2%/2mm. Profiles at all field sizes and depths
showed excellent agreement with the minimum percentage of pixels passing each individual
profile being 94.8% and 91.0% for 6MV and 10MV models, respectively. The average
percentage of pixels passing the gamma analysis was 99.4% and 99.6% for 6MV and 10MV
models respectively. Table 3.4 displays the average agreement by field size for both 6MV and
10MV models.

45

Validation Results – Dose Profile Data
% Pixels Passing
Field Size (cm2)
Elekta 6MV Model

Elekta 10MV Model

3x3

99.0

99.6

5x5

99.5

100.0

10 x 10

99.5

100.0

15 x 15

99.4

99.5

20 x 20

99.8

99.9

30 x 30

99.4

99.9

Table 3.4: Gamma comparison agreement for Elekta 6MV and 10MV models using a
±2%/2mm criterion for measured and calculated dose profile data. Dose profiles were
measured and calculated in-plane and cross-plane at depths of dmax (1.6cm for 6MV and 2.0cm
for 10MV), 5cm, 10cm, 20cm, and 25cm (10MV only).

3.3 Benchmark Testing
3.3.1 Uncertainty
The measurement uncertainty in the dose distributions in the radiochromic film, normalized
to the adjacent TLD doses, was estimated in previous studies to be between 2.6% and 3.5% at
one standard deviation[12, 35]. By normalizing the film to the TLD dose, the uncertainty related
to differences between the film calibration process and the actual film used in benchmarking
was minimized. The literature details the estimated uncertainty of the TLD dose[11], the film
uniformity, film-to-film variation, and the fit of the sensitometric curve[71].
The estimated single voxel standard error of the mean in the phantom plan simulations was
1.1% using 12 million particles per square centimeter.
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3.3.2 Deliver of IMRT H&N Phantom Plan: Point Dose Comparison
Results comparing TLD measurements to predicted doses by the multiple source model are
shown in Table 3.5 for the Elekta 6MV model and Table 3.6 for the Elekta 10MV model. TLD
capsules were contained within the center of the primary PTV (four capsules), center of the
secondary PTV (two capsules) and the center of a mock organ at risk (two capsules). Included
in the table are average dose measurements, percent standard deviation from the three
deliveries of each plan, a comparison of the DPM predicted dose with measurement expressed
as a ratio of calculated dose to measured dose, and, for reference, a comparison of Pinnacle
calculated dose with measurement expressed as a ratio of calculated to measured dose.
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TLD
Measurement

DPM Calculation

Pinnacle Calculation

Point Dose

Avg.

% Std.

Avg.

% Std.

Ratio

Avg.

% Std.

Ratio

Location

(cGy)

Dev.

(cGy)

Dev.

Calc/Meas

(cGy)

Dev.

Calc/Meas

Pri – SP

644.7

0.7

672.5

1.9

1.043

667.8

0.7

1.036

Pri – SA

654.9

0.1

655.1

1.9

1.000

666.6

0.7

1.018

Pri – IP

634.9

0.7

649.4

2.1

1.023

664.7

0.6

1.047

Pri –IA

646.3

0.7

638.6

2.0

0.988

664.9

0.7

1.029

Pri Avg.

1.014

1.032

Sec – S

527.3

0.4

529.6

1.4

1.004

542.1

0.5

1.028

Sec – I

523.6

0.1

521.6

2.0

0.996

542.1

0.2

1.035

Sec Avg.

1.000

1.032

OAR – S

277.1

0.2

288.2

11.7

1.040

316.7

1.3

1.143

OAR – I

294.6

0.4

304.5

10.0

1.033

339.0

1.4

1.151

OAR Avg.

1.037

1.147

Table 3.5: Point dose comparisons for the Elekta 6MV IMRT head and neck phantom
measurements. The measured dose is the averaged dose from the three deliveries of each
plan. Comparison to calculated doses by DPM (left) and Pinnacle (right) are expressed as a
ratio of calculated to measured doses. Point dose locations are indicated by Pri = Primary PTV,
Sec = Secondary PTV, OAR = Organ at Risk, S = Superior, I = Inferior, A = Anterior, P =
Posterior.
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For the Elekta 6MV model the average agreement between the DPM multiple source model
calculation and measurement in the primary PTV was 1.014. The range of calculated to
measured dose ratios was from 0.988 to 1.043. The secondary PTV showed an average
agreement of 1.000 with a range from 0.996 to 1.004. The averaged ratio for the OAR TLD was
1.037 with a range of 1.033 to 1.040. The poorer agreement with the OAR measured dose
could largely be attributed to the high dose gradient in the region due to the OAR’s close
proximity to the primary PTV.

49

TLD Measurement

DPM Calculation

Pinnacle Calculation

Point Dose

Avg.

% Std.

Avg.

% Std.

Ratio

Avg.

% Std.

Ratio

Location

(cGy)

Dev.

(cGy)

Dev.

Calc/Meas

(cGy)

Dev.

Calc/Meas

Pri – SP

625.1

0.4

676.8

2.0

1.083

677.0

0.8

1.083

Pri – SA

657.2

0.3

645.2

1.7

0.982

672.7

1.5

1.024

Pri – IP

639.4

0.2

658.2

1.7

1.029

676.3

0.7

1.058

Pri –IA

662.1

0.8

653.4

2.1

0.987

686.7

0.7

1.037

Pri Avg.

1.020

1.050

Sec – S

531.0

0.5

529.4

1.4

0.997

550.8

0.0

1.037

Sec – I

526.8

0.7

520.2

1.0

0.987

551.0

0.0

1.046

Sec Avg.

0.992

1.042

OAR – S

252.9

0.9

288.9

7.9

1.142

307.4

0.4

1.216

OAR – I

260.5

0.6

297.4

6.2

1.141

321.5

0.3

1.234

OAR Avg.

1.142

1.225

Table 3.6: Point dose comparisons for the Elekta 10MV IMRT head and neck phantom
measurements. The measured dose is the averaged dose from the three deliveries of each
plan. Comparison to calculated doses by DPM (left) and Pinnacle (right) are expressed as a
ratio of calculated to measured doses. Point dose locations are indicated by Pri = Primary PTV,
Sec = Secondary PTV, OAR = Organ at Risk, S = Superior, I = Inferior, A = Anterior, P =
Posterior.
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Results for the Elekta 10MV model show an average agreement between the DPM code
and measurement in the primary PTV of 1.020. The range contributing to this average was
from 0.982 to 1.083. The poor agreement seen in the superior posterior TLD is suspected to be
due to its proximity to a high dose gradient. Further examination of the dose field showed that a
setup error as small as 1.5mm could contribute to the 8% change in dose. Agreement in the
secondary PTV was 0.992 with a range of 0.987 to 0.997. Comparisons in the OAR showed an
average agreement of 1.142 with a range of 1.141 to 1.142. Similar to the 6MV model, the OAR
showed an overall poorer agreement with measurement. This was again attributed to the high
dose gradient in the region.
While the benchmarking of the multiple source model was based exclusively on
measurement, comparisons to doses calculated by Pinnacle are included as means of
comparison against an actively used and state of the art treatment planning system dose
calculation algorithm. A comparison between average agreement of DPM to measured doses
and Pinnacle to measured doses shows superior performance for the Monte Carlo based
calculation technique.

3.3.3 Delivery of IMRT H&N Phantom Plan: Dose Profile and Gamma Map Comparison
Dose profile comparison between the multiple source model and measurement are shown
for all three major planes in Figures 3.17, 3.18, 3.19 for the 6MV model and Figures 3.20, 3.21,
and 3.22 for the 10MV model. These comparisons are meant to be a qualitative assessment of
the models ability to predict complex dose distributions across the volume of the PTV. All
profiles showed good agreement between calculation and measurement.
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Figure 3.17: A comparison of the lateral (left to right) profile from the axial film of an IMRT H&N
delivery for the 6MV model (delivery #1).

Figure 3.18: A comparison of the AP (anterior to posterior) profile from the axial film of an
IMRT H&N delivery for the 6MV model (delivery #1).
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Figure 3.19: A comparison of the SI (superior to inferior) profile from the axial film of an IMRT
H&N delivery for the 6MV model (delivery #1).

Figure 3.20: A comparison of the lateral (left to right) profile from the axial film of an IMRT H&N
delivery for the 10MV model (delivery #1).
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Figure 3.21: A comparison of the AP (anterior to posterior) profile from the axial film of an
IMRT H&N delivery for the 10MV model (delivery #1).

Figure 3.22: A comparison of the SI (superior to inferior) profile from the axial film of an IMRT
H&N delivery for the 10MV model (delivery #1).
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To evaluate the models performance at describing the penumbra, MLC leakage, rounded
leaf tips, and leaf transmission in highly modulated fields, gamma analysis was performed
using a ±3%/2mm criterion. The analysis considers dose differences as relative percentage
and the distance to agreement to assess overall agreement and identify locations of difficulty to
the model. The resulting gamma maps from a single irradiation in the axial and sagittal plans
are shown in Figure 3.23 and Figure 3.24 for the 6MV model and Figure 3.25 and Figure 3.26
for the 10MV model. Gamma maps for all three deliveries of each nominal energy are included
in the Appendix. For the IMRT head and neck plan, the average percent of pixels passing for
the 6MV comparison was 87.2% with a range of 82.5% to 91.4%. The 10MV comparison
averaged 90.5% of pixels passing the ±3%/2mm criterion with a range of 86.4% to 95.9%.
Table 3.7 reports the average agreement in the sagittal and axial planes for both the 6MV and
10MV models.

Elekta 6MV

Elekta 10MV

Axial

Sagittal

Axial

Sagittal

Delivery #1

91.4

88.9

91.3

87.9

Delivery #2

87.6

86.7

91.6

86.4

Delivery #3

82.5

86.1

95.9

87.3

Average

87.2

87.3

92.9

87.2

Table 3.7: Percentage of pixels passing a ±3%/2mm gamma criterion for IMRT head and neck
plans for both Elekta 6MV and 10MV models. Agreement was evaluated in both the axial and
sagittal planes for three deliveries of each plan.
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Figure 3.23: IMRT head and neck delivery comparison for the axial plane of delivery #1 for the
Elekta 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 91.4% of
pixels passed.

Figure 3.24: IMRT head and neck delivery comparison for the sagittal plane of delivery #1 for
the Elekta 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
88.9% of pixels passed.
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Figure 3.25: IMRT head and neck delivery comparison for the axial plane of delivery #3 for the
Elekta 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 95.9%
of pixels passed.

Figure 3.26: IMRT head and neck delivery comparison for the sagittal plane of delivery #3 for
the Elekta 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
87.3% of pixels passed.
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Qualitative evaluation of the axial gamma maps revealed no consistent failure regions in the
dose distribution for either the 6MV or 10MV comparisons. Failure regions of the sagittal
gamma maps were consistently along the posterior edge of the PTV in the superior film piece
for both 6MV and 10MV comparisons. This is largely attributed to the sensitivity of the
comparison to the registration of film to the phantom. Because the sagittal comparisons consist
of two pieces of film that need to be aligned during scanning, the registration uncertainty is
higher than for the axial plane which consists of single piece of film. Dose profiles shown in
Figure 3.27 suggest that there could be an approximately 1mm offset in the alignment of the
superior piece of film with respect to the inferior piece of film. Even with the increased
registration uncertainty, passing rates were above the pre-established threshold of 85%.
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Figure 3.27: Dose profile comparison for IMRT head and neck delivery for 10MV Elekta model.
The top profile is along the anteroposterior direction of the superior film piece, and the bottom
is along the anteroposterior direction of the inferior film piece.
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3.3.4 Delivery of SBRT Thorax Phantom Plan: Point Dose Comparison
The results to point dose comparisons between the developed model and TLD
measurements in the anthropomorphic thorax phantom are shown in Table 3.8 and Table 3.9.
Double packed TLD were contained in the center of the target (two), in the heart (one), and in
the spinal cord (one). The table includes average dose measurements, percent standard
deviation from the three deliveries of each plan, a comparison of the DPM predicted dose with
measurement expressed as a ratio of calculated dose to measured dose, and, for reference, a
comparison of Pinnacle calculated doses with measurement expressed as a ratio of measured
to calculated dose.

TLD
Measurement

DPM Calculation

Pinnacle Calculation

Point Dose

Avg.

% Std.

Avg.

% Std.

Ratio

Avg.

% Std.

Ratio

Location

(cGy)

Dev.

(cGy)

Dev.

Calc/Meas

(cGy)

Dev.

Calc/Meas

PTV – S

657.6

0.4

677.2

0.7

1.030

658.0

3.0

1.001

PTV – I

659.8

0.3

679.1

0.7

1.029

661.7

2.8

1.003

PTV Avg.

1.030

1.002

OAR – Heart

99.0

0.2

107.4

2.1

1.085

99.6

5.8

1.006

OAR – Cord

122.6

0.4

130.3

1.8

1.062

136.8

2.4

1.115

Table 3.8: Point dose comparisons for the Elekta 6MV SBRT lung phantom measurements.
The measured dose is the averaged dose from the three deliveries of each plan. Comparison
to calculated doses by DPM (left) and Pinnacle (right) are expressed as a ratio of calculated to
measured doses. Point dose locations are indicated by PTV = Planning Target Volume, OAR =
Organ at Risk, S = Superior, I = Inferior.
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For the Elekta 6MV model the average agreement between the DPM multiple source model
calculation and measurement in the PTV was 1.030. The range of calculated to measured dose
ratios was from 1.029 to 1.030. The ratio for the heart TLD was 1.085, and the ratio for the cord
TLD was 1.062.

TLD Measurement

DPM Calculation

Pinnacle Calculation

Point Dose

Avg.

% Std.

Avg.

% Std.

Ratio

Avg.

% Std.

Ratio

Location

(cGy)

Dev.

(cGy)

Dev.

Calc/Meas

(cGy)

Dev.

Calc/Meas

PTV – S

664.5

0.2

679.1

1.0

1.022

672.8

3.1

1.012

PTV – I

675.0

0.7

681.6

0.8

1.010

674.9

3.1

1.000

PTV Avg.

1.016

1.006

OAR – Heart

99.1

0.2

105.2

4.1

1.061

100.5

7.1

1.014

OAR – Cord

122.5

0.8

130.0

0.0

1.061

136.2

2.9

1.112

Table 3.9: Point dose comparisons for the Elekta 10MV SBRT lung phantom measurements.
The measured dose is the averaged dose from the three deliveries of each plan. Comparison
to calculated doses by DPM (left) and Pinnacle (right) are expressed as a ratio of calculated to
measured doses. Point dose locations are indicated by PTV = Planning Target Volume, OAR =
Organ at Risk, S = Superior, I = Inferior.

The average agreement between the DPM model and the PTV for the Elekta 10MV model
was 1.016. The range of the values for the PTV agreement was from 1.010 to 1.022. The
calculated to measured ratio for both the heart and cord TLDs was 1.061.
It is important to note that while the OAR calculated doses showed poorer agreement with
measurements for 6MV and 10MV models, the uncertainty in the measured dose is unknown at
such low doses. The standards used for low dose measurements are done at doses of 8Gy
61

and 3Gy, nearly 3 times the dose of both the heart and cord measurement for the lower of the
two standard doses. At doses near 1Gy, as seen in both of the OAR TLD, the RPC does not
have data documenting the accuracy of their TLD measurement process for phantom
irradiations.
Even though the benchmarking of the multiple source model was based exclusively on
measurement, comparisons to doses calculated by Pinnacle are included as means of
comparison against an actively used and state of the art treatment planning system dose
calculation algorithm. A direct comparison between the DPM calculated doses and the Pinnacle
calculated doses show the DPM calculation to be comparable with measurement results in the
OARs and within the PTVs.

3.3.5 Delivery of SBRT Thorax Phantom Plan: Dose Profile and Gamma Map Comparison
Dose profile comparison between the multiple source model and measurement are shown
for all three major planes in Figures 3.28, 3.29, 3.30 for the 6MV model and Figures 3.31, 3.32,
and 3.33 for the 10MV model. These comparisons are meant to be a qualitative assessment of
the models ability to predict complex dose distributions across the volume of the PTV. All
profiles showed good agreement between calculation and measurement.
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Figure 3.28: A comparison of the lateral (left to right) profile from the axial film of an SBRT lung
delivery for the 6MV model (delivery #1).

Figure 3.29: A comparison of the AP (anterior to posterior) profile from the axial film of an
SBRT lung delivery for the 6MV model (delivery #1).
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Figure 3.30: A comparison of the SI (superior to inferior) profile from the sagittal film of an
SBRT lung delivery for the 6MV model (delivery #1).

Figure 3.31: A comparison of the lateral (left to right) profile from the axial film of an SBRT lung
delivery for the 10MV model (delivery #1).
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Figure 3.32: A comparison of the AP (anterior to posterior) profile from the axial film of an
SBRT lung delivery for the 10MV model (delivery #1).

Figure 3.33: A comparison of the SI (superior to inferior) profile from the sagittal film of an
SBRT lung delivery for the 10MV model (delivery #1).

The models ability to describe the beam penumbra, MLC leakage, rounded leaf tips, and
leaf transmission in unmodulated fields in a heterogeneous medium provided by the lung
phantom was evaluated using the gamma technique with a ±3%/2mm criterion. The analysis
considers the dose differences as a percentage of the maximum dose and distance to
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agreement to assess overall agreement between dose distributions calculated by the multiple
source model and measured by the radiochromic film in the phantom. In this way resulting
gamma maps can be used to identify areas where the model may be deficient while allowing
for positional measurement uncertainty to be accounted for in the distance to agreement
criterion.
The gamma maps for a single irradiation and comparison to source model calculation for the
6MV model are showing in Figures 3.34, 3.35, and 3.36 for the axial, sagittal, and coronal
planes respectively. Gamma maps for each delivery are included in the Appendix. The average
agreement, expressed as a percentage of pixels passing the gamma criterion, were 86.8%,
86.9%, and 87.8% for axial, sagittal, and coronal planes, respectively. Agreement for the axial
plane ranged from 85.3% to 89.0%. Agreement for the sagittal plane ranged from 85.9% to
87.7%, and the range of agreement for the coronal plane was 84.2% to 93.9%.

Figure 3.34: Lung SBRT delivery comparison for the axial plane of delivery #1 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 85.3% of pixels
passed.
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Figure 3.35: Lung SBRT delivery comparison for the sagittal plane of delivery #1 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 87.7% of pixels
passed.

Figure 3.36: Lung SBRT delivery comparison for the coronal plane of delivery #1 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 93.9% of pixels
passed.
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The gamma maps corresponding to the comparison of a single irradiation to the calculated
dose of the 10MV source model are showing in Figures 3.37, 3.38, and 3.39 for axial, sagittal,
and coronal planes, respectively. Gamma maps from all other deliveries are included in the
Appendix for reference. The average agreement was 90.2%, 88.3%, and 89.5% for axial,
sagittal, and coronal planes, respectively. The range of values for the axial plane was 86.2% to
96.5%, for the sagittal plane 85.2% to 90.8%, and for the coronal plane 85.3% to 92.6%.

Figure 3.37: Lung SBRT delivery comparison for the axial plane of delivery #1 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 96.5% of
pixels passed.
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Figure 3.38: Lung SBRT delivery comparison for the sagittal plane of delivery #1 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 89.1% of
pixels passed.

Figure 3.39: Lung SBRT delivery comparison for the coronal plane of delivery #1 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 92.6% of
pixels passed.
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The passing rate of comparisons for each plane for all three deliveries with respect to the
DPM source model calculation is shown for both 6MV and 10MV models in Table 3.10.
Elekta 6MV

Elekta 10MV

Axial

Sagittal

Coronal

Axial

Sagittal

Coronal

Delivery #1

85.3

87.7

93.9

96.5

89.1

92.6

Delivery #2

86.2

85.9

85.3

86.2

90.8

85.3

Delivery #3

89.0

87.0

84.2

88.1

85.2

90.5

Average

86.8

86.9

87.8

90.2

88.3

89.5

Table 3.10: Percentage of pixels passing a ±3%/2mm gamma criterion for SBRT lung plans for
both Elekta 6MV and 10MV models. Agreement was evaluated in the axial, sagittal, and
coronal planes for three deliveries of each plan.

A qualitative evaluation of the gamma maps showed no consistent failure regions in the
comparison in the axial plane. The agreement in the sagittal and coronal planes appeared to be
challenged most at the edges of the PTV. This is largely attributed to the sensitivity of the
comparison to the registration of film to the phantom. Because both film plane comparisons
consist of two pieces of film that need to be aligned during scanning, the registration
uncertainty is higher than for the axial plane which consists of single piece of film. Furthermore
the high dose gradients at the edges of the PTV make the analysis more sensitive to a small
translational shift either in the film registration or phantom setup. Even with the increased
registration uncertainty, passing rates were above the pre-established threshold of 85%.
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3.3.6 Delivery of IMRT Thorax Phantom Plan: Point Dose Comparison
The results of the point dose comparisons between the developed model and TLD
measurements in the anthropomorphic thorax phantom are shown in Table 3.11 and Table
3.12. Double packed TLD were contained in the center of the target (two), in the heart (one),
and in the spinal cord (one). The table includes dose measurements, a comparison of the DPM
predicted dose with measurement expressed as a ratio of calculated dose to measured dose,
and, for reference, a comparison of Pinnacle calculated doses with measurement expressed as
a ratio of measured to calculated dose.
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TLD
Measurement

DPM Calculation

Pinnacle Calculation

Point Dose

Avg.

% Std.

Avg.

% Std.

Ratio

Avg.

% Std.

Ratio

Location

(cGy)

Dev.

(cGy)

Dev.

Calc/Meas

(cGy)

Dev.

Calc/Meas

PTV – S

611.9

0.4

614.0

0.7

1.003

611.9

0.5

1.000

PTV – I

607.9

0.4

610.5

0.3

1.004

608.2

0.5

1.000

PTV Avg.

1.004

1.000

OAR – Heart

98.1

0.8

90.0

0.0

0.917

94.9

3.7

0.967

OAR – Cord

221.7

0.4

227.0

1.8

1.024

212.8

6.9

0.960

Table 3.11: Point dose comparisons for the Elekta 6MV IMRT lung phantom measurements.
The measured dose is the averaged dose from the three deliveries of each plan. Comparison
to calculated doses by DPM (left) and Pinnacle (right) are expressed as a ratio of calculated to
measured doses. Point dose locations are indicated by PTV = Planning Target Volume, OAR =
Organ at Risk, S = Superior, I = Inferior.

For the Elekta 6MV model the average agreement between the DPM multiple source model
calculation and measurement in the PTV was 1.004. The range of calculated to measured dose
ratios within the PTV was 1.003 to 1.004. The ratio for the heart TLD was 0.917, and the ratio
for the cord TLD was 1.024.
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TLD Measurement

DPM Calculation

Pinnacle Calculation

Point Dose

Avg.

% Std.

Avg.

% Std.

Ratio

Avg.

% Std.

Ratio

Location

(cGy)

Dev.

(cGy)

Dev.

Calc/Meas

(cGy)

Dev.

Calc/Meas

PTV – S

594.6

0.4

608.4

1.6

1.023

622.8

0.6

1.047

PTV – I

591.4

0.1

602.2

0.8

1.018

613.8

0.6

1.038

PTV Avg.

1.021

1.043

OAR – Heart

95.8

0.3

90.0

0.0

0.940

97.5

3.0

1.018

OAR – Cord

242.5

0.5

234.8

6.4

0.968

234.6

7.6

0.967

Table 3.12: Point dose comparisons for the Elekta 10MV IMRT lung phantom measurements.
The measured dose is the averaged dose from the three deliveries of each plan. Comparison
to calculated doses by DPM (left) and Pinnacle (right) are expressed as a ratio of calculated to
measured doses. Point dose locations are indicated by PTV = Planning Target Volume, OAR =
Organ at Risk, S = Superior, I = Inferior.

The average agreement between the DPM model and the PTV for the Elekta 10MV model
was 1.021. The range of the values for the PTV agreement was from 1.018 to 1.023. The
calculated to measured ratio for the heart and cord TLDs were 0.940 and 0.968, respectively.
It is important to note that while the OAR calculated doses showed poorer agreement with
measurements for 6MV and 10MV models, the uncertainty in the measured dose is unknown at
such low doses. The standards used for low dose measurements are done at doses of 8Gy
and 3Gy, nearly 3 times the dose of both the heart and cord measurement for the lower of the
two standard doses. At doses near 1Gy, as seen in both of the OAR TLD, the RPC does not
have data documenting the accuracy of their TLD measurement process for phantom
irradiations.
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Even though the benchmarking of the multiple source model was based exclusively on
measurement, comparisons to doses calculated by Pinnacle are included as means of
comparison against an actively used and state of the art treatment planning system dose
calculation algorithm. A direct comparison between the DPM calculated dose performance to
the Pinnacle calculated dose performance shows superior results in the PTV TLD capsules and
comparable performance within the OARs.

3.3.7 Delivery of IMRT Thorax Phantom Plan: Dose Profile and Gamma Map Comparison
Dose profile comparison between the multiple source model and measurement are shown
for all three major planes in Figures 3.40, 3.41, 3.42 for the 6MV model and Figures 3.43, 3.44,
and 3.45 for the 10MV model. These comparisons are meant to be a qualitative assessment of
the models ability to predict complex dose distributions across the volume of the PTV. All
profiles showed good agreement between calculation and measurement.

Figure 3.40: A comparison of the lateral (left to right) profile from the axial film of an IMRT lung
delivery for the 6MV model.
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Figure 3.41: A comparison of the AP (anterior to posterior) profile from the axial film of an
IMRT lung delivery for the 6MV model.

Figure 3.42: A comparison of the SI (superior to inferior) profile from the coronal film of an
IMRT lung delivery for the 6MV model.
75

Figure 3.43: A comparison of the lateral (left to right) profile from the axial film of an IMRT lung
delivery for the 10MV model.

Figure 3.44: A comparison of the AP (anterior to posterior) profile from the axial film of an
IMRT lung delivery for the 10MV model.
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Figure 3.45: A comparison of the SI (superior to inferior) profile from the coronal film of an
IMRT lung delivery for the 10MV model.

The models ability to describe the beam penumbra, MLC leakage, rounded leaf tips, and
leaf transmission in unmodulated fields in a heterogeneous medium provided by the lung
phantom was evaluated using the gamma technique with a ±3%/2mm criterion. The analysis
considers the dose differences as a percentage of the maximum dose and distance to
agreement to assess overall agreement between dose distributions calculated by the multiple
source model and measured by the radiochromic film in the phantom. In this way resulting
gamma maps can be used to identify areas where the model may be deficient while allowing
for positional measurement uncertainty to be accounted for in the distance to agreement
criterion.
The gamma maps and comparison to source model calculation for the 6MV model are
showing in Figures 3.46, 3.47, and 3.48 for the axial, sagittal, and coronal planes respectively.
The agreement, expressed as a percentage of pixels passing the gamma criterion, were
85.2%, 90.0%, and 88.6% for axial, sagittal, and coronal planes, respectively. The individual
passing rates for each film plane in each deliver are presented in Table 3.12.
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Figure 3.46: Lung IMRT delivery comparison for the axial plane of delivery #3 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 87.5% of pixels
passed.

Figure 3.47: Lung IMRT delivery comparison for the sagittal plane of delivery #3 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 86.4% of pixels
passed.
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Figure 3.48: Lung IMRT delivery comparison for the coronal plane of delivery #3 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 94.0% of pixels
passed.

The gamma maps corresponding to the comparison of a single irradiation to the calculated
dose of the 10MV source model are shown in Figures 3.49, 3.50, and 3.51 for axial, sagittal,
and coronal planes, respectively. The agreement was 91.2%, 90.6%, and 88.0% for axial,
sagittal, and coronal planes, respectively. Individual passing rates for each plane in each
delivery are presented in Table 3.13.
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Elekta 6MV

Elekta 10MV

Axial

Sagittal

Coronal

Axial

Sagittal

Coronal

Delivery #1

82.6

92.5

89.8

94.7

90.6

89.29

Delivery #2

85.4

83.5

89.8

86.6

87.3

86.03

Delivery #3

87.5

94.0

86.4

92.5

94.0

88.53

Average

85.2

90.0

88.6

91.2

90.6

88.0

Table 3.13: Percentage of pixels passing a ±3%/2mm gamma criterion for IMRT lung plans for
both Elekta 6MV and 10MV models. Agreement was evaluated in the axial, sagittal, and
coronal planes for three deliveries of each plan.

Figure 3.49: Lung IMRT delivery comparison for the axial plane of delivery #1 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 94.7% of
pixels passed.
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Figure 3.50: Lung IMRT delivery comparison for the sagittal plane of delivery #1 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 90.6% of
pixels passed.

Figure 3.51: Lung IMRT delivery comparison for the coronal plane of delivery #1 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 89.3% of
pixels passed.
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A qualitative evaluation of the gamma maps showed no consistent failure regions in the
comparison in the axial plane. The agreement in the sagittal and coronal planes appeared to be
challenged most at the edges of the PTV. This is largely attributed to the sensitivity of the
comparison to the registration of film to the phantom. Because both film plane comparisons
consist of two pieces of film that need to be aligned during scanning, the registration
uncertainty is higher than for the axial plane which consists of single piece of film. Furthermore
the high dose gradients at the edges of the PTV make the analysis more sensitive to a small
translational shift either in the film registration or phantom setup. Even with the increased
registration uncertainty, passing rates were above the pre-established threshold of 85%.

3.3.8 Benchmark Summary
The average and range of the percent of pixels passing a ±3%/2mm global gamma criterion
for each phantom for both Elekta 6MV and 10MV source models is presented in Table 3.14.

IMRT H&N

SBRT Lung

IMRT Lung

Elekta

Average

87.2

87.2

87.9

6MV

Range

82.5 – 91.4

84.2 – 93.9

82.6 – 94.0

Elekta

Average

90.5

89.3

89.9

10MV

Range

86.4 – 95.9

85.2 – 96.5

86.0 – 94.7

Table 3.14: The average and range of the percent of pixels passing a ±3%/2mm gamma
criterion for Elekta 6MV and 10MV source models as assessed through three repeated
deliveries for three different treatment plans to anthropomorphic phantoms.
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Each multiple source model was benchmarked against three progressively challenging
treatment plans delivered to anthropomorphic phantoms using SBRT and IMRT techniques in
homogeneous and heterogeneous media. A 9 co-planar beam IMRT plan was designed and
delivered to a head and neck phantom for both 6MV and 10MV nominal energies. Agreement
was assessed using the gamma technique with a passing criterion of ±3% of the maximum
dose and ±2mm distance to agreement. The average percent of pixels passing the criterion
was 87.2% and 90.5% for 6MV and 10MV models, respectively. The models showed a range of
passing percentages in the sagittal and axial planes of 82.5% to 91.4% for the 6MV model and
86.4% to 95.9% for the 10MV model. In general disagreement was limited to the edges of the
PTV in the sagittal plane where measurement uncertainty associated with film registration was
most likely to have an effect on the analysis due to the steep dose gradient in the region.
An un-modulated, 9 co-planar beam SBRT plan was delivered to the RPC’s
anthropomorphic lung phantom. Each beam was defined by a static MLC configuration
designed to conform the dose to the PTV. The average percent of pixels passing a ±3%/2mm
global gamma criterion was 87.2% and 89.3% for 6MV and 10MV models, respectively. The
range of pixels passing for the 6MV model was 84.2% to 93.9% and 85.2% to 96.5% for the
10MV model. Similar to the head and neck benchmark results, the only consistent region of
disagreement was along the edges of the PTV in the sagittal and coronal planes in the regions
of the steepest dose gradient.
Moderately modulated, 6 co-planar beam, 6MV and 10MV IMRT plans were delivered to the
anthropomorphic lung phantom. The addition of modulation to the heterogeneous phantom
increased the challenge to the dose calculation tool while maintaining a clinically relevant
setup. The average percent of pixels passing a ±3%/2mm global gamma criterion was 87.9%
and 89.9% for 6MV and 10MV models, respectively. The range of pixels passing the ±3%/2mm
criterion was 82.6% to 94.0% for the 6MV model and 86.0% to 94.7% for the 10MV model.
Even with the increased difficulty of the calculation conditions, disagreement between
measurement and calculation was minimal.
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3.4 Conclusion
An analytical, multiple source model for Elekta 6MV and 10MV beams using the Dose
Planning Method (DPM) Monte Carlo code was developed and validated within ±2% of the
maximum dose and ±2mm distance to agreement against open field depth dose and dose
profile measurements for field sizes ranging from 3 x 3 cm 2 to 30 x 30 cm2. On average 99.5%
and 99.6% of the data tested for 6MV and 10MV models, respectively, met the above criterion
using gamma analysis.
The first step in the commissioning process used measured percent depth dose data from a
nominal 10 x 10 cm2 field size to determine the energy spectra and relative fluences for a
primary point source and an extra-focal disk source through an optimization process fitting
relative contributions of 0.25 MeV energy bins to a Fatigue-Fermi Distribution. In the same
optimization process the relative contribution of an electron disk source was determined.
Particle distribution was implemented directly from the literature for the extra-focal[60] and
electron[53] sources.
The second step of the commissioning process matched measured and calculated dose
profiles for an open 40 x 40 cm2 field in order to model the increase in off-axis fluence. The
decrease in mean energy off-axis was implemented without change from Tailor et al[61]. An
output correction was empirically applied to match the increased scatter contribution with
increasing field size. Upon completion of the commissioning process an accurate model of
Elekta 6MV and 10MV therapeutic x-ray beams was developed to run basic open beam dose
calculations using the DPM Monte Carlo code.
The commissioned and validated multiple source models were then benchmarked against
increasingly challenging treatment plans delivered to homogenous and heterogeneous
anthropomorphic phantoms. The model was shown to be accurate within ±3% and ±2mm
based on comparisons of calculated dose to enclosed thermoluminescent dosimeters (TLD)
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and radiochromic film. Average agreement assessed using the gamma technique and a
3%/2mm global criterion was 87.4% and 89.9% for 6MV and 10MV source models,
respectively.
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Chapter 4: Results and Discussion: Varian TrueBeam 6 MV and 10MV Flattening Filter
Free Beams
4.1 Source Model
4.1.1 Source Model Commissioning Parameters
The seven optimized parameters, determined in commissioning, that describe the photon
energy spectra, fluence contributions, and volume averaging of the ion chamber leading to an
exaggerated penumbra for dose profiles are reported in Table 4.1 for the Varian TrueBeam
FFF 6MV and 10MV models. The first three parameters, γ, μ, and β describe the spectrum
shape, peak energy location, and relative scale respectively. Figure 4.1 and Figure 4.2 show a
graphical comparison between the Varian TrueBeam FFF models and the Varian models with
the flattening filter in place developed by Davidson et al.[35] for nominal energies of 6MV and
10MV, respectively.

86

Parameter
Fatigue-Life distribution shape parameter, γ
Fatigue-Life distribution location parameter, μ
Fatigue-Life distribution scale parameter, β

Value

Value

TrueBeam FFF 6MV

TrueBeam FFF 10MV

9.00

12.50

0.0500

-0.0154

3.50

3.88

4.28

4.47

0.0900

0.1003

0.0025

0.0015

1.2

1.2

Primary spectrum to extra-focal spectrum
reduction factor
Extra-focal fluence relative to the primary
fluence
Electron Contamination contribution (relative to
the primary photon contribution)
Standard deviation of Gaussian used to convolve
the MC dose profile to match the measured dose
profile during validation (in mm)

Table 4.1: Optimized parameters for the source models as determined during the initial
commissioning of the models. The first three parameters describe the shape and location of the
spectra. The fourth through sixth parameters relate the relative contribution and energy scale of
the three sources, and the final parameter is the standard deviation of the Gaussian kernel
convolved with the calculated dose profiles to mimic the volume averaging effect of an ion
chamber at the penumbra of dose profiles.
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Figure 4.1: Comparison of commissioned TrueBeam FFF 6MV source model spectrum (red
square) with the previously developed Varian 6MV source model (blue diamond)[35].
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Figure 4.2: Comparison of commissioned TrueBeam FFF 10MV source model spectrum (red
square) with the previously developed Varian 10MV source model (blue diamond)[35].

The extra-focal source was scaled in energy by a factor of 4.28 and 4.47 for 6MV and 10MV
models, respectively. Their fluences, relative to the primary point source in a 10 x 10 cm2 open
field, were found to be 9.00% and 10.03% for 6MV and 10MV models, respectively. The
electron contamination sources, while small at 0.25% and 0.15%, respectively, were still
included in the source model, unlike the Varian 6MV model[20, 21, 35]. For the comparison of
the dose profiles, a Gaussian kernel of standard deviation 1.2mm was convolved with the
calculated data to model the volume averaging effect of an ion chamber measurement.
The results to the second step of the commissioning process in which the off-axis fluence
was modeled by a piecewise linear function of the cosine of the off-axis angle are shown in
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Table 4.2. The off-axis energy correction was implemented from Georg et al.[62] without
change.

Fluence Weight (Relative to CAX)

Fluence Weight (Relative to CAX)

TrueBeam FFF 6MV Model

TrueBeam FFF 10 MV Model

1.00000

1.0000

1.0000

0.99970

0.9597

0.9010

0.99789

0.8973

0.7852

0.99728

0.8310

0.6850

0.99518

0.7563

0.5950

0.99250

0.6939

0.5260

0.98926

0.6299

0.4609

0.98546

0.5759

0.4073

0.98113

0.5191

0.3490

0.97630

0.4600

0.1591

0.97098

0.4000

0.1167

0.96277

0.3400

0.0700

Cosine (Off-axis Angle)

Table 4.2: Optimized coefficients to a piece-wise linear function used to describe the increase
in off-axis fluence of TrueBeam FFF 6MV and 10MV models. Fluence weighting values are
reported with respect to the dose measured at the central axis (CAX) for the 40 x 40 cm2 field
size dose profile at a depth of dmax.

After completing the second step of the commissioning process, the scaling factor used to
convert the Monte Carlo output from energy per particle to cGy per MU was determined from
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the dose at dmax along the central axis for a 10 x 10 cm2 field size. These values were 41.79
and 29.49 for the 6MV and 10MV models, respectively. This factor will be applied to all
subsequent dose calculations for the corresponding energy models.

4.1.2 Fluence Map, Primary Source Size, and Machine Output Correction
Fluence map generation is a process that is unique to the treatment plan, patient, phantom,
or open field delivery, and beam energy. The MLC positions for each segment weight the
fluence by assuming 1% transmission through the leaves and an additional 1% as interleaf
leakage. The transmission and the leakage percentages were the same for 6MV and 10MV
models.
Because the source model includes a point source representing photons created within the
target and not a finite source size, an offset of the MLC, xpen, of 0.4mm was necessary. This
was the same offset used in the Varian model[20, 21, 35] and because the literature has
suggested its size is nearly fixed for different nominal energies from the same
manufacturer[69], it was left constant for both 6MV and 10MV models.
Unlike the previously developed Varian[35] and Elekta (Chapter 3) models, an empirically
determined field size dependent output correction was not needed to match the calculated to
measured dosimetry data. This is likely due to the difference in scatter contributions when
removing the flattening filter from the linear accelerator head.

4.2 Validation Testing
4.2.1 Uncertainty
The uncertainty in the ion chamber measurements was estimated at 1.6% (one standard
deviation) to match that reported in the literature[70]. The standard error of the mean in the
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dose calculations was calculated to be no more than 1.2% using the batch method described in
AAPM Task Group Report No. 105[22].

4.2.2 Depth Dose Data
The comparison between measured and calculated percent depth dose data for the
TrueBeam FFF 6MV and 10MV models was performed for field sizes ranging from 3 x 3 cm 2 to
40 x 40 cm2. Gamma analysis agreement using a ±2%/2mm criterion is summarized in Table
4.3. The percentage of data passing the criterion for every field size at every depth is reported
in the Appendix (Chapter 7). For a graphical comparison between depth dose curves of all field
sizes please see the Appendix (Chapter 7). As representative summary the smallest (3 x 3 cm
2

), nominal (10 x 10 cm2), and largest (40 x 40 cm2) field sizes are shown for the TrueBeam

FFF 6MV model in Figures 4.3, 4.4, and 4.5, respectively. The same field sizes are shown for
the TrueBeam FFF 10MV model in Figure 4.6, 4.7, and 4.8, respectively.
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Validation Results –Depth Dose Data
% Pixels Passing
Field Size (cm2)
TrueBeam FFF 6MV Model

TrueBeam FFF 10MV Model

3x3

100.0

99.3

4x4

100.0

99.3

6x6

99.3

99.3

8x8

100.0

100.0

10 x 10

100.0

100.0

20 x 20

100.0

100.0

30 x 30

100.0

97.4

40 x 40

100.0

96.7

Table 4.3: Gamma comparison agreement for TrueBeam FFF 6MV and 10MV models using a
±2%/2mm criterion for measured and calculated depth dose data
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Figure 4.3: Calculated (blue ‘x’) and measured (red line) depth dose curves for a TrueBeam
FFF 6MV beam for a 3 x 3 cm 2 field size. Gamma agreement (red circles) for each point is also
displayed along with any points (red star) at which a failure to meet the ±2%/2mm criterion.

Figure 4.4: Calculated (blue ‘x’) and measured (red line) depth dose curves for a TrueBeam
FFF 6MV beam for a 10 x 10 cm2 field size. Gamma agreement (red circles) for each point is
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion.
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Figure 4.5: Calculated (blue ‘x’) and measured (red line) depth dose curves for a TrueBeam
FFF 6MV beam for a 40 x 40 cm2 field size. Gamma agreement (red circles) for each point is
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion.

Figure 4.6: Calculated (blue ‘x’) and measured (red line) depth dose curves for a TrueBeam
FFF 10MV beam for a 3 x 3 cm 2 field size. Gamma agreement (red circles) for each point is
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion.
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Figure 4.7: Calculated (blue ‘x’) and measured (red line) depth dose curves for a TrueBeam
FFF 10MV beam for a 10 x 10 cm2 field size. Gamma agreement (red circles) for each point is
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion.

Figure 4.8: Calculated (blue ‘x’) and measured (red line) depth dose curves for a TrueBeam
FFF 10MV beam for a 40 x 40 cm2 field size. Gamma agreement (red circles) for each point is
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion.
96

4.2.3 Dose Profiles
A comparison of calculated dose profiles to measurements was performed for both
TrueBeam FFF 6MV and FFF 10MV models at depths of dmax, 5cm, 10cm, 20cm, and 30cm for
field sizes ranging from 3 x 3 cm 2 to 40 x 40cm2. Gamma analysis with ±2%/2mm criteria was
used as the means of comparison and is summarized in Table 4.4. The percentages of pixels
passing for each profile compared are reported in the Appendix (Chapter 6) along with graphs
of each comparison. As a representative summary the smallest (3 x 3 cm 2), nominal (10 x 10
cm2), and largest (40 x 40 cm2) field sizes are shown for the TrueBeam FFF 6MV model in
Figures 4.9, 4.10, and 4.11, respectively. The same field sizes are shown for the FFF 10MV
model in Figure 4.12, 4.13, and 4.14, respectively.
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Validation Results – Dose Profile Data
% Pixels Passing
Field Size (cm2)
TrueBeam FFF 6MV Model

TrueBeam FFF 10MV Model

3x3

99.4

98.9

4x4

99.0

99.7

6x6

99.6

99.6

8x8

99.2

98.3

10 x 10

98.7

96.2

20 x 20

95.4

98.5

30 x 30

95.3

96.1

40 x 40

96.1

95.7

Table 4.4: Gamma comparison agreement for TrueBeam FFF 6MV and FFF 10MV models
using a ±2%/2mm criterion for measured and calculated dose profile data. Dose profiles were
measured and calculated in-plane at depths of dmax (1.6cm for 6MV and 2.4cm for 10MV), 5cm,
10cm, 20cm, and 30cm.
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Figure 4.9: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam FFF
6MV beam at a field size of 3 x 3 cm 2.

Figure 4.10: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
FFF 6MV beam at a field size of 10 x 10 cm2.
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Figure 4.11: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
FFF 6MV beam at a field size of 40 x 40 cm2.

Figure 4.12: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
FFF 10MV beam at a field size of 3 x 3 cm 2.
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Figure 4.13: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
FFF 10MV beam at a field size of 10 x 10 cm2.

Figure 4.14: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
FFF 10MV beam at a field size of 40 x 40 cm2.
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Agreement between calculated and measured profile data was assessed using the gamma
technique with an evaluation criterion of ±2%/2mm. Profiles at all field sizes and depths
showed good agreement with the minimum percentage of pixels passing being 88.0% and
88.6% for 6MV and 10MV models respectively. The average percentage of pixels passing the
gamma analysis was 97.8% and 97.9% for 6MV and 10MV models, respectively. Table 4.4
displays the average agreement by field size for both 6MV and 10MV models.
Among the 40 profiles compared for the TrueBeam FFF 6MV model, 5 failed to achieve the
pre-established minimum of 90% of pixels passing a ±2%/2mm gamma criterion. These failures
occurred at field sizes of 20 x 20 cm2 at depths of 1.5cm (88.0%) and 5cm (89.0%), 30 x 30
cm2 at depths of 1.5cm (88.1%) and 5cm (89.0%), and 40 x 40 cm2 at a depth of 1.5cm
(89.9%). Among the profiles compared for the TrueBeam FFF 10MV model, a single profile at a
depth of 2.4cm for a field size of 40 x 40 cm2 failed to meet the 90% requirement (88.6%).
Failure points for both models were located in the low dose region just beyond the penumbra
for all failing profiles. It is suspected that the model over predicts the scatter dose at these
points just outside the field edge. Because all failing profiles were within 2% of the preestablished criterion and occurred for larger field sizes only, it was determined that the
disagreement would have minimal impact on the use of the calculation model for flattening filter
free beams. One of the primary advantages of a flattening filter free beam is the increased
dose rate achieved by removing the flattening filter and by extension reduced treatment time.
For larger field sizes a higher degree of modulation is required to achieve desirable dose
distributions due to the lack of flatness of the beam. This negates, and sometimes makes
worse, the reduced treatment time achieved from the higher dose rate. It is therefore unlikely
that a clinical plan would use field sizes at the size of the failing profiles.
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4.3 Benchmark Testing
4.3.1 Uncertainty
The measurement uncertainty in the dose distributions in the radiochromic film, normalized
to the adjacent TLD doses, was estimated in previous studies to be between 2.6% and 3.5% at
one standard deviation[12, 35]. By normalizing the film to the TLD dose, the uncertainty related
to differences between the film calibration process and the actual film used in benchmarking
was minimized. The literature details the estimated uncertainty of the TLD dose[11], the film
uniformity, film-to-film variation, and the fit of the sensitometric curve[71].
The estimated single voxel standard error of the mean in the phantom plan simulations was
1.0% using 12 million particles per square centimeter.

4.3.2 Delivery of the IMRT Head and Neck Phantom Plan: Point Dose Comparison
Results comparing TLD measurements to predicted doses by the multiple source model are
shown in Table 4.5 for the TrueBeam FFF 6MV model and Table 4.6 for the TrueBeam FFF
10MV model. TLD capsules were contained within the center of the primary PTV (four
capsules), center of the secondary PTV (two capsules) and the center of a mock organ at risk
(two capsules). Included in the table are average dose measurements, percent standard
deviation from the three deliveries of each plan, a comparison of the DPM predicted dose with
measurement expressed as a ratio of calculated dose to measured dose, and, for reference, a
comparison of Eclipse calculated dose with measurement expressed as a ratio of calculated to
measured dose.
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TLD
Measurement

DPM Calculation

Eclipse Calculation

Point Dose

Avg.

% Std.

Avg.

% Std.

Ratio

Avg.

% Std.

Ratio

Location

(cGy)

Dev.

(cGy)

Dev.

Calc/Meas

(cGy)

Dev.

Calc/Meas

Pri – SP

663.7

0.2

654.4

1.0

0.986

668.0

1.4

1.006

Pri – SA

680.8

0.2

664.8

0.7

0.976

681.9

1.7

1.002

Pri – IP

660.5

0.6

653.6

0.6

0.990

665.9

0.0

1.008

Pri –IA

672.2

0.6

660.4

0.8

0.983

674.0

1.9

1.003

Pri Avg.

0.984

1.005

Sec – S

571.8

0.4

568.9

0.4

0.995

577.8

2.3

1.010

Sec – I

567.5

0.4

552.7

0.9

0.974

569.5

2.1

1.003

Sec Avg.

0.984

1.007

OAR – S

286.8

0.3

290.9

0.8

1.014

297.2

4.8

1.036

OAR – I

295.7

0.6

299.5

1.1

1.013

302.4

0.0

1.023

OAR Avg.

1.014

1.029

Table 4.5: Point dose comparisons for the FFF 6MV IMRT head and neck phantom
measurements. The measured dose is the averaged dose from the three deliveries of each
plan. Comparison to calculated doses by DPM (left) and Eclipse (right) are expressed as a ratio
of calculated to measured doses. Point dose locations are indicated by Pri = Primary PTV, Sec
= Secondary PTV, OAR = Organ at Risk, S = Superior, I = Inferior, A = Anterior, P = Posterior.
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For the TrueBeam FFF 6MV model the average agreement between the DPM multiple
source model calculation and measurement in the primary PTV was 0.984. The range of
calculated to measured dose ratios was 0.976 to 0.990. The secondary PTV showed an
average agreement of 0.984 with a range of 0.974 to 0.995. The averaged ratio for the OAR
TLD was 1.014 with a range of 1.013 to 1.014.
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TLD Measurement

DPM Calculation

Eclipse Calculation

Point Dose

Avg.

% Std.

Avg.

% Std.

Ratio

Avg.

% Std.

Ratio

Location

(cGy)

Dev.

(cGy)

Dev.

Calc/Meas

(cGy)

Dev.

Calc/Meas

Pri – SP

658.3

0.7

670.0

0.6

1.018

662.7

1.9

1.007

Pri – SA

662.5

0.4

671.5

0.7

1.014

666.0

0.0

1.005

Pri – IP

660.1

0.7

676.4

0.6

1.025

665.1

0.0

1.008

Pri –IA

658.7

0.7

672.4

0.6

1.021

665.0

0.0

1.010

Pri Avg.

1.019

1.007

Sec – S

559.7

1.3

565.6

0.4

1.010

563.3

1.1

1.006

Sec – I

556.8

0.3

568.2

0.4

1.020

562.1

2.4

1.009

Sec Avg.

1.015

1.008

OAR – S

288.2

1.0

328.2

0.7

1.139

305.2

0.0

1.059

OAR – I

289.7

1.1

325.2

0.0

1.123

302.4

2.9

1.044

OAR Avg.

1.131

1.051

Table 4.6: Point dose comparisons for the FFF 10MV IMRT head and neck phantom
measurements. The measured dose is the averaged dose from the three deliveries of each
plan. Comparison to calculated doses by DPM (left) and Eclipse (right) are expressed as a ratio
of calculated to measured doses. Point dose locations are indicated by Pri = Primary PTV, Sec
= Secondary PTV, OAR = Organ at Risk, S = Superior, I = Inferior, A = Anterior, P = Posterior.
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Results for the TrueBeam FFF 10MV model show an average agreement between the DPM
code and measurement in the primary PTV of 1.019. The range contributing to this average
was from 1.014 to 1.025. Agreement in the secondary PTV was 1.015 with a range of 1.010 to
1.020. Comparisons in the OAR showed an average agreement of 1.131 with a range of 1.123
to 1.139. The poorer agreement with measurement displayed in the OAR was attributed to the
high dose gradient in the region that was necessary to meet the plan criteria.
While the benchmarking of the multiple source model was based exclusively on
measurement, comparisons to doses calculated by Eclipse are included as means of
comparison against an actively used and state of the art treatment planning system dose
calculation algorithm. A comparison between average agreement of DPM to measured doses
and Eclipse to measured doses shows superior agreement for the Eclipse results in both FFF
6MV and FFF 10MV models. The superior performance in Eclipse calculations in the PTV was
limited to being no more than 1.1% and 1.2% better for FFF 6MV and FFF 10MV models,
respectively.

4.3.3 Delivery of the IMRT Head and Neck Phantom Plan: Dose Profile and Gamma Map
Comparison
Dose profile comparison between the multiple source model and measurement are shown
for all three major planes in Figures 4.15, 4.16, and 4.17 for the 6MV model and Figures 4.18,
4.19, and 4.20 for the 10MV model. These comparisons are meant to be a qualitative
assessment of the models ability to predict complex dose distributions across the volume of the
PTV. All profiles showed good agreement between calculation and measurement.
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Figure 4.15: A comparison of the lateral (left to right) profile from the axial film of an IMRT H&N
delivery for the FFF 6MV model (delivery #1).

Figure 4.16: A comparison of the AP (anterior to posterior) profile from the axial film of an
IMRT H&N delivery for the FFF 6MV model (delivery #1).
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Figure 4.17: A comparison of the SI (superior to inferior) profile from the axial film of an IMRT
H&N delivery for the FFF 6MV model (delivery #1).

Figure 4.18: A comparison of the lateral (left to right) profile from the axial film of an IMRT H&N
delivery for the FFF 10MV model (delivery #1).
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Figure 4.19: A comparison of the AP (anterior to posterior) profile from the axial film of an
IMRT H&N delivery for the FFF 10MV model (delivery #1).

Figure 4.20: A comparison of the SI (superior to inferior) profile from the axial film of an IMRT
H&N delivery for the FFF 10MV model (delivery #1).
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To evaluate the models performance at describing the penumbra, MLC leakage, rounded
leaf tips, and leaf transmission in highly modulated fields, gamma analysis was performed
using a ±3%/2mm criterion. The analysis considers dose differences as relative percentage
and the distance to agreement to assess overall agreement and identify locations of difficulty to
the model. The resulting gamma maps from a single irradiation in the axial and sagittal plans
are shown in Figure 4.21 and Figure 4.22 for the 6MV model and Figure 4.23 and Figure 4.24
for the 10MV model. Gamma maps for all three deliveries of each nominal energy are included
in the Appendix. For the IMRT head and neck plan, the average percent of pixels passing for
the 6MV comparison was 90.1% with a range of 80.3% to 95.9%. The 10MV comparison
averaged 87.2% of pixels passing the ±3%/2mm criterion with a range of 75.5% to 93.1%.
Table 4.7 reports the average agreement in the sagittal and axial planes for both the 6MV and
10MV models.

TrueBeam FFF 6MV

TrueBeam FFF 10MV

Axial

Sagittal

Axial

Sagittal

Delivery #1

93.6

94.3

87.9

90.5

Delivery #2

89.4

86.6

93.1

85.9

Delivery #3

80.3

95.9

75.5

90.1

Average

87.8

92.3

85.5

88.8

Table 4.7: Percentage of pixels passing a ±3%/2mm gamma criterion for IMRT head and neck
plans for both TrueBeam FFF 6MV and 10MV models. Agreement was evaluated in both the
axial and sagittal planes for three deliveries of each plan.
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Figure 4.21: IMRT head and neck delivery comparison for the axial plane of delivery #1 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
93.6% of pixels passed.

Figure 4.22: IMRT head and neck delivery comparison for the sagittal plane of delivery #1 for
the TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 94.3% of pixels passed.
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Figure 4.23: IMRT head and neck delivery comparison for the axial plane of delivery #1 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 87.9% of pixels passed.

Figure 4.24: IMRT head and neck delivery comparison for the sagittal plane of delivery #1 for
the TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 90.5% of pixels passed.
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Qualitative evaluation of the axial gamma maps suggested that the model was challenged
most near the OAR where the dose gradient would be steepest. Failure regions of the sagittal
gamma maps were consistent with the axial gamma maps in suggesting that the model was
challenged most posterior to the PTV in the region near the OAR. Even with the increased
challenge near the steep dose gradient, passing rates were above the pre-established
threshold of 85%.

4.3.4 Delivery of the SBRT Thorax Phantom Plan: Point Dose Comparison
The results to point dose comparisons between the developed model and TLD
measurements in the anthropomorphic thorax phantom are shown in Table 4.8 and Table 4.9.
Double packed TLD were contained in the center of the target (two), in the heart (one), and in
the spinal cord (one). The table includes average dose measurements, percent standard
deviation from the three deliveries of each plan, a comparison of the DPM predicted dose with
measurement expressed as a ratio of calculated dose to measured dose, and, for reference, a
comparison of Eclipse calculated doses with measurement expressed as a ratio of measured to
calculated dose.
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TLD
Measurement

DPM Calculation

Eclipse Calculation

Point Dose

Avg.

% Std.

Avg.

% Std.

Ratio

Avg.

% Std.

Ratio

Location

(cGy)

Dev.

(cGy)

Dev.

Calc/Meas

(cGy)

Dev.

Calc/Meas

PTV – S

788.2

0.4

796.7

0.5

1.011

812.9

0.0

1.031

PTV – I

783.0

0.1

786.3

0.4

1.004

803.1

0.5

1.026

PTV Avg.

1.007

1.028

OAR – Heart

170.6

0.4

177.5

1.7

1.040

168.8

0.0

0.989

OAR – Cord

155.2

0.0

177.5

2.6

1.144

179.4

2.6

1.156

Table 4.8: Point dose comparisons for the FFF 6MV SBRT lung phantom measurements. The
measured dose is the averaged dose from the three deliveries of each plan. Comparison to
calculated doses by DPM (left) and Eclipse (right) are expressed as a ratio of calculated to
measured doses. Point dose locations are indicated by PTV = Planning Target Volume, OAR =
Organ at Risk, S = Superior, I = Inferior.

For the TrueBeam FFF 6MV model the average agreement between the DPM multiple
source model calculation and measurement in the PTV was 1.007. The range of calculated to
measured dose ratios was 1.004 to 1.011. The ratio for the heart TLD was 1.040, and the ratio
for the cord TLD was 1.144.
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TLD Measurement

DPM Calculation

Eclipse Calculation

Point Dose

Avg.

% Std.

Avg.

% Std.

Ratio

Avg.

% Std.

Ratio

Location

(cGy)

Dev.

(cGy)

Dev.

Calc/Meas

(cGy)

Dev.

Calc/Meas

PTV – S

819.6

0.6

828.3

0.6

1.011

836.6

0.6

1.021

PTV – I

813.9

0.4

810.0

2.1

0.995

821.3

0.6

1.009

PTV Avg.

1.003

1.015

OAR – Heart

155.5

0.7

152.0

2.6

0.978

155.0

0.0

0.997

OAR – Cord

150.5

0.5

170.0

0.0

1.130

169.9

0.0

1.129

Table 4.9: Point dose comparisons for the FFF 10MV SBRT lung phantom measurements. The
measured dose is the averaged dose from the three deliveries of each plan. Comparison to
calculated doses by DPM (left) and Eclipse (right) are expressed as a ratio of calculated to
measured doses. Point dose locations are indicated by PTV = Planning Target Volume, OAR =
Organ at Risk, S = Superior, I = Inferior.

The average agreement between the DPM model and the PTV for the TrueBeam FFF 10MV
model was 1.003. The range of the values for the PTV agreement was 0.995 to 1.011. The
calculated to measured ratios for the heart and cord TLDs were 0.978 and 1.130, respectively.
It is important to note that while the OAR calculated doses showed poorer agreement with
measurements for 6MV and 10MV models, the uncertainty in the measured dose is unknown at
such low doses. The standards used for low dose measurements are done at doses of 8Gy
and 3Gy, nearly 3 times the dose of both the heart and cord measurement for the lower of the
two standard doses. At doses near 1Gy, as seen in both of the OAR TLD, the RPC does not
have data documenting the accuracy of their TLD measurement process for phantom
irradiations.
116

Even though the benchmarking of the multiple source model was based exclusively on
measurement, comparisons to doses calculated by Eclipse are included as means of
comparison against an actively used and state of the art treatment planning system dose
calculation algorithm. A direct comparison between the DPM calculated doses and the Eclipse
calculated doses show the DPM calculation to agree better with measurement results in the
PTVs and comparably within the OARs.

4.3.5 Delivery of the SBRT Thorax Phantom Plan: Dose Profile and Gamma Map
Comparison
Dose profile comparison between the multiple source model and measurement are shown
for all three major planes in Figures 4.25, 4.26, 4.27 for the FFF 6MV model and Figures 4.28,
4.29, and 4.30 for the FFF 10MV model. These comparisons are meant to be a qualitative
assessment of the models ability to predict complex dose distributions across the volume of the
PTV. All profiles showed good agreement between calculation and measurement.

Figure 4.25: A comparison of the lateral (left to right) profile from the axial film of an SBRT lung
delivery for the FFF 6MV model (delivery #1).
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Figure 4.26: A comparison of the AP (anterior to posterior) profile from the axial film of an
SBRT lung delivery for the FFF 6MV model (delivery #1).

Figure 4.27: A comparison of the SI (superior to inferior) profile from the sagittal film of an
SBRT lung delivery for the FFF 6MV model (delivery #1).
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Figure 4.28: A comparison of the lateral (left to right) profile from the axial film of an SBRT lung
delivery for the FFF 10MV model (delivery #1).

Figure 4.29: A comparison of the AP (anterior to posterior) profile from the axial film of an
SBRT lung delivery for the FFF 10MV model (delivery #1).
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Figure 4.30: A comparison of the SI (superior to inferior) profile from the sagittal film of an
SBRT lung delivery for the FFF 10MV model (delivery #1).

The models ability to describe the beam penumbra, MLC leakage, rounded leaf tips, and
leaf transmission in unmodulated fields in a heterogeneous medium provided by the lung
phantom was evaluated using the gamma technique with a ±3%/2mm criterion. The analysis
considers the dose differences as a percentage of the maximum dose and distance to
agreement to assess overall agreement between dose distributions calculated by the multiple
source model and measured by the radiochromic film in the phantom. In this way resulting
gamma maps can be used to identify areas where the model may be deficient while allowing
for positional measurement uncertainty to be accounted for in the distance to agreement
criterion.
The gamma maps for a single irradiation and comparison to source model calculation for the
6MV model are showing in Figures 4.31, 4.32, and 4.33 for the axial, sagittal, and coronal
planes, respectively. Gamma maps for each delivery are included in the Appendix. The
average agreement, expressed as a percentage of pixels passing the gamma criterion, were
87.8%, 90.4%, and 94.2% for axial, sagittal, and coronal planes, respectively. Agreement for
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the axial plane ranged from 84.5% to 91.5%. Agreement for the sagittal plane ranged from
85.5% to 95.2%, and the range of agreement for the coronal plane was 85.5% to 98.7%.

Figure 4.31: Lung SBRT delivery comparison for the axial plane of delivery #1 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
91.5% of pixels passed.
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Figure 4.32: Lung SBRT delivery comparison for the sagittal plane of delivery #1 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
85.5% of pixels passed.

Figure 4.33: Lung SBRT delivery comparison for the coronal plane of delivery #1 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
98.7% of pixels passed.
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The gamma maps corresponding to the comparison of a single irradiation to the calculated
dose of the 10MV source model are showing in Figures 4.34, 4.35, and 4.36 for axial, sagittal,
and coronal planes, respectively. Gamma maps from all other deliveries are included in the
Appendix for reference. The average agreement was 91.5%, 89.5%, and 94.2% for axial,
sagittal, and coronal planes, respectively. The range of values for the axial plane was 87.4% to
95.8%, for the sagittal plane 88.1% to 91.4%, and for the coronal plane 91.9% to 98.1%.

Figure 4.34: Lung SBRT delivery comparison for the axial plane of delivery #1 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 91.4% of pixels passed.
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Figure 4.35: Lung SBRT delivery comparison for the sagittal plane of delivery #1 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 88.9% of pixels passed.

Figure 4.36: Lung SBRT delivery comparison for the coronal plane of delivery #1 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 91.9% of pixels passed.
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The passing rate of comparisons for each plane for all three deliveries with respect to the
DPM source model calculation is shown for both 6MV and 10MV models in Table 4.10.
TrueBeam FFF 6MV

TrueBeam FFF 10MV

Axial

Sagittal

Coronal

Axial

Sagittal

Coronal

Delivery #1

91.5

85.5

98.7

91.4

88.9

91.9

Delivery #2

84.5

90.3

98.4

87.4

88.1

92.7

Delivery #3

87.5

95.2

85.5

95.8

91.4

98.1

Average

87.8

90.4

94.2

90.2

88.3

89.5

Table 4.10: Percentage of pixels passing a ±3%/2mm gamma criterion for SBRT lung plans for
both TrueBeam FFF 6MV and FFF 10MV models. Agreement was evaluated in the axial,
sagittal, and coronal planes for three deliveries of each plan.

A qualitative evaluation of the gamma maps showed no consistent failure regions in the
comparison in the axial plane. The agreement in the sagittal and coronal planes appeared to be
challenged most at the edges of the PTV. This is largely attributed to the sensitivity of the
comparison to the registration of film to the phantom. Because both film plane comparisons
consist of two pieces of film that need to be aligned during scanning, the registration
uncertainty is higher than for the axial plane which consists of single piece of film. Furthermore
the high dose gradients at the edges of the PTV make the analysis more sensitive to a small
translational shift either in the film registration or phantom setup. Even with the increased
registration uncertainty, passing rates were above the pre-established threshold of 85%.
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4.3.6 Delivery of the IMRT Thorax Phantom Plan: Point Dose Comparison
The results to point dose comparisons between the developed model and TLD
measurements in the anthropomorphic thorax phantom are shown in Table 4.11 and Table
4.12. Double packed TLD were contained in the center of the target (two), in the heart (one),
and in the spinal cord (one). The table includes dose measurements, a comparison of the DPM
predicted dose with measurement expressed as a ratio of calculated dose to measured dose,
and, for reference, a comparison of Eclipse calculated doses with measurement expressed as
a ratio of calculated to measured dose.
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TLD
Measurement

DPM Calculation

Eclipse Calculation

Point Dose

Avg.

% Std.

Avg.

% Std.

Ratio

Avg.

% Std.

Ratio

Location

(cGy)

Dev.

(cGy)

Dev.

Calc/Meas

(cGy)

Dev.

Calc/Meas

PTV – S

625.4

0.5

616.7

0.8

0.986

636.0

0.7

1.017

PTV – I

625.1

1.0

630.0

1.2

1.008

644.1

0.0

1.030

PTV Avg.

0.997

1.024

OAR – Heart

62.5

1.0

58.0

8.4

0.927

60.0

8.3

0.959

OAR – Cord

47.5

0.4

50.0

0.0

1.054

57.8

0.0

1.218

Table 4.11: Point dose comparisons for the FFF 6MV IMRT lung phantom measurements. The
measured dose is the averaged dose from the three deliveries of each plan. Comparison to
calculated doses by DPM (left) and Eclipse (right) are expressed as a ratio of calculated to
measured doses. Point dose locations are indicated by PTV = Planning Target Volume, OAR =
Organ at Risk, S = Superior, I = Inferior.

For the TrueBeam FFF 6MV model the average agreement between the DPM multiple
source model calculation and measurement in the PTV was 0.997. The range of calculated to
measured dose ratios was 0.986 to 1.008. The ratio for the heart TLD was 0.927, and the ratio
for the cord TLD was 1.054.
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TLD Measurement

DPM Calculation

Eclipse Calculation

Point Dose

Avg.

% Std.

Avg.

% Std.

Ratio

Avg.

% Std.

Ratio

Location

(cGy)

Dev.

(cGy)

Dev.

Calc/Meas

(cGy)

Dev.

Calc/Meas

PTV – S

624.2

0.5

630.0

0.0

1.009

631.0

0.0

1.011

PTV – I

643.4

0.5

630.0

0.0

0.979

626.9

0.0

0.974

PTV Avg.

0.994

0.993

OAR – Heart

62.4

1.3

68.0

0.0

1.090

61.5

8.0

0.985

OAR – Cord

52.5

0.8

50.0

0.0

0.953

51.0

0.0

0.972

Table 4.12: Point dose comparisons for the FFF 10MV IMRT lung phantom measurements.
The measured dose is the averaged dose from the three deliveries of each plan. Comparison
to calculated doses by DPM (left) and Eclipse (right) are expressed as a ratio of calculated to
measured doses. Point dose locations are indicated by PTV = Planning Target Volume, OAR =
Organ at Risk, S = Superior, I = Inferior.

The average agreement between the DPM model and the PTV for the TrueBeam FFF 10MV
model was 0.994. The range of the values for the PTV agreement was 0.979 to 1.009. The
calculated to measured ratio for the heart and cord TLDs were 1.090 and 0.953, respectively.
It is important to note that while the OAR calculated doses showed poorer agreement with
measurements for 6MV and 10MV models, the uncertainty in the measured dose is unknown at
such low doses. The standards used for low dose measurements are done at doses of 8Gy
and 3Gy, nearly 3 times the dose of both the heart and cord measurement for the lower of the
two standard doses. At doses near 1Gy, as seen in both of the OAR TLD, the RPC does not
have data documenting the accuracy of their TLD measurement process for phantom
irradiations.
128

Even though the benchmarking of the multiple source model was based exclusively on
measurement, comparisons to doses calculated by Eclipse are included as means of
comparison against an actively used and state of the art treatment planning system dose
calculation algorithm. A direct comparison between the DPM calculated dose performance to
the Eclipse calculated dose performance shows comparable results in the PTV TLD capsules
and inferior performance within the OARs.

4.3.7 Delivery of the IMRT Thorax Phantom Plan: Dose Profile and Gamma Map
Comparison
Dose profile comparison between the multiple source model and measurement are shown
for all three major planes in Figures 4.37, 4.38, 4.39 for the 6MV model and Figures 4.40, 4.41,
and 4.42 for the 10MV model. These comparisons are meant to be a qualitative assessment of
the models ability to predict complex dose distributions across the volume of the PTV. All
profiles showed good agreement between calculation and measurement.

Figure 4.37: A comparison of the lateral (left to right) profile from the axial film of an IMRT lung
delivery for the FFF 6MV model (delivery #1).

129

Figure 4.38: A comparison of the AP (anterior to posterior) profile from the axial film of an
IMRT lung delivery for the FFF 6MV model (delivery #1).

Figure 4.39: A comparison of the SI (superior to inferior) profile from the sagittal film of an
IMRT lung delivery for the FFF 6MV model (delivery #1).
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Figure 4.40: A comparison of the lateral (left to right) profile from the axial film of an IMRT lung
delivery for the FFF 10MV model (delivery #1).

Figure 4.41: A comparison of the AP (anterior to posterior) profile from the axial film of an
IMRT lung delivery for the FFF 10MV model (delivery #1).
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Figure 4.42: A comparison of the SI (superior to inferior) profile from the sagittal film of an
IMRT lung delivery for the FFF 10MV model (delivery #1).

The models ability to describe the beam penumbra, MLC leakage, rounded leaf tips, and
leaf transmission in unmodulated fields in a heterogeneous medium provided by the lung
phantom was evaluated using the gamma technique with a ±3%/2mm criterion. The analysis
considers the dose differences as a percentage of the maximum dose and distance to
agreement to assess overall agreement between dose distributions calculated by the multiple
source model and measured by the radiochromic film in the phantom. In this way resulting
gamma maps can be used to identify areas where the model may be deficient while allowing
for positional measurement uncertainty to be accounted for in the distance to agreement
criterion.
The gamma maps for a single irradiation and comparison to source model calculation for the
FFF 6MV model are showing in Figures 4.43, 4.44, and 4.45 for the axial, sagittal, and coronal
planes respectively. Gamma maps for each delivery are included in the Appendix. The average
agreement, expressed as a percentage of pixels passing the gamma criterion, were 92.0%,
91.2%, and 91.5% for axial, sagittal, and coronal planes, respectively. Agreement for the axial
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plane ranged from 91.0% to 93.5%. Agreement for the sagittal plane ranged from 87.4% to
94.3%, and the range of agreement for the coronal plane was 88.4% to 93.9%.

Figure 4.43: Lung IMRT delivery comparison for the axial plane of delivery #1 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
91.0% of pixels passed.
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Figure 4.44: Lung IMRT delivery comparison for the sagittal plane of delivery #1 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
91.8% of pixels passed.

Figure 4.45: Lung IMRT delivery comparison for the coronal plane of delivery #1 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
93.9% of pixels passed.
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The gamma maps corresponding to the comparison of a single irradiation to the calculated
dose of the FFF 10MV source model are showing in Figures 4.46, 4.47, and 4.48 for axial,
sagittal, and coronal planes, respectively. Gamma maps from all other deliveries are included
in the Appendix for reference. The average agreement was 95.3%, 89.9%, and 95.0% for axial,
sagittal, and coronal planes, respectively. The range of values for the axial plane was 93.0% to
97.4%, for the sagittal plane 85.2% to 93.6%, and for the coronal plane 92.1% to 96.6%.

Figure 4.46: Lung IMRT delivery comparison for the axial plane of delivery #3 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 92.3% of pixels passed.
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Figure 4.47: Lung IMRT delivery comparison for the sagittal plane of delivery #3 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 90.8% of pixels passed.

Figure 4.48: Lung IMRT delivery comparison for the coronal plane of delivery #3 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 96.6% of pixels passed.
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The passing rate of comparisons for each plane for all three deliveries with respect to the
DPM source model calculation is shown for both FFF 6MV and FFF 10MV models in Table
4.13.
TrueBeam FFF 6MV

TrueBeam FFF 10MV

Axial

Sagittal

Coronal

Axial

Sagittal

Coronal

Delivery #1

91.0

91.8

93.9

95.6

85.2

92.1

Delivery #2

91.4

87.4

88.4

97.4

93.6

96.4

Delivery #3

93.5

94.3

92.4

93.0

90.8

96.6

Average

92.0

90.4

91.5

95.3

89.9

95.0

Table 4.13: Percentage of pixels passing a ±3%/2mm gamma criterion for IMRT lung plans for
both TrueBeam FFF 6MV and 10MV models. Agreement was evaluated in the axial, sagittal,
and coronal planes for three deliveries of each plan.

A qualitative evaluation of the gamma maps showed the model was challenged most along
the edges of the beam profile outside of the PTV region. This region is more sensitive to the
rotational positioning of the film during scanning because of the combination of the steeper
dose gradient and the increased distance from the axis of rotation at the center of the film. The
agreement in the sagittal and coronal planes appeared to be challenged most at the edges of
the PTV. This is largely attributed to the sensitivity of the comparison to the registration of film
to the phantom. Additionally, the film measurement for the FFF 6MV comparisons yielded
doses lower than 1Gy at the corners of the axial films. At doses in this region the sensitometric
curve used results in lower accuracy of the measured dose. Because both film plane
comparisons consist of two pieces of film that need to be aligned during scanning, the
registration uncertainty is higher than for the axial plane which consists of single piece of film.
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Furthermore the high dose gradients at the edges of the PTV make the analysis more sensitive
to a small translational shift either in the film registration or phantom setup. Even with the
increased registration and position uncertainty, passing rates were above the pre-established
threshold of 85%.

4.3.8 Benchmark Summary
The average and range of the percent of pixels passing a ±3%/2mm global gamma criterion
for each phantom for both TrueBeam FFF 6MV and FFF 10MV source models is presented in
Table 4.14.

IMRT H&N

SBRT Lung

IMRT Lung

TrueBeam

Average

90.0

90.8

89.6

FFF 6MV

Range

80.3 – 95.9

84.5 – 98.4

85.1 – 97.5

TrueBeam

Average

87.2

91.7

93.4

FFF 10MV

Range

75.5 – 93.1

87.4 – 98.1

85.2 – 97.4

Table 4.14: The average and range of the percent of pixels passing a ±3%/2mm gamma
criterion for TrueBeam FFF 6MV and FFF 10MV source models as assessed through three
repeated deliveries for three different treatment plans to anthropomorphic phantoms.

Each multiple source model was benchmarked against three progressively challenging
treatment plans delivered to anthropomorphic phantoms using SBRT and IMRT techniques in
homogeneous and heterogeneous media. A 9 co-planar beam IMRT plan was designed and
delivered to a head and neck phantom for both FFF 6MV and FFF 10MV nominal energies.
Agreement was assessed using the gamma technique with a passing criterion of ±3% of the
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maximum dose and ±2mm distance to agreement. The average percent of pixels passing the
criterion was 90.0% and 87.2% for FFF 6MV and FFF 10MV models, respectively. The models
showed a range of passing percentages in the sagittal and axial planes of 80.3% to 95.9% for
the FFF 6MV model and 75.5% to 93.1% for the FFF 10MV model. In general disagreement
was limited to regions near the organ at risk where the dose gradient was greatest.
An un-modulated, 9 co-planar beam SBRT plan was delivered to the RPC’s
anthropomorphic lung phantom. Each beam was defined by a static MLC configuration
designed to conform the dose to the PTV. The average percent of pixels passing a ±3%/2mm
global gamma criterion was 90.8% and 91.7% for 6MV and 10MV models, respectively. The
range of pixels passing for the FFF 6MV model was 84.5% to 98.4% and 87.4% to 98.1% for
the FFF 10MV model.
Moderately modulated, 6 co-planar beam, FFF 6MV and FFF 10MV IMRT plans were
delivered to the anthropomorphic lung phantom. The addition of modulation to the
heterogeneous phantom increased the challenge to the dose calculation tool while maintaining
a clinically relevant setup. The average percent of pixels passing a ±3%/2mm global gamma
criterion was 89.6% and 93.4% for FFF 6MV and FFF 10MV models, respectively. The range of
pixels passing the criterion was 85.1% to 97.5% for the FFF 6MV model and 85.2% to 97.4%
for the FFF 10MV model. Even with the increased difficulty of the calculation conditions,
disagreement between measurement and calculation was minimal.

4.4 Conclusion
An analytical, multiple source model for TrueBeam FFF 6MV and FFF 10MV beams using
the Dose Planning Method (DPM) Monte Carlo code was developed and validated within ±2%
of the maximum dose and ±2mm distance to agreement against open field depth dose and
dose profile measurements for field sizes ranging from 3 x 3 cm 2 to 40 x 40 cm2. On average
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98.1% of the data tested for both 6MV and 10MV models met the above criterion using gamma
analysis.
The first step in the commissioning process used measured percent depth dose data from a
nominal 10 x 10 cm2 field size to determine the energy spectra and relative fluences for a
primary point source and an extra-focal disk source through an optimization process fitting
relative contributions of 0.25 MeV energy bins to a Fatigue-Fermi Distribution. In the same
optimization process the relative contribution of an electron disk source was determined.
Particle distribution was implemented directly from the literature for the extra-focal[60] and
electron[53] sources.
The second step of the commissioning process matched measured and calculated dose
profiles for an open 40 x 40 cm2 field in order to model the increase in off-axis fluence. The
decrease in mean energy off-axis was implemented without change from Georg et al[62]. Upon
completion of the commissioning process an accurate model of TrueBeam FFF 6MV and FFF
10MV therapeutic x-ray beams was developed to run basic open beam dose calculations using
the DPM Monte Carlo code.
The commissioned and validated multiple source models were then benchmarked against
increasingly challenging treatment plans delivered to homogenous and heterogeneous
anthropomorphic phantoms. The model was shown to be accurate within ±3% and ±2mm
based on comparisons of calculated dose to enclosed thermoluminescent dosimeters (TLD)
and radiochromic film. Average agreement assessed using the gamma technique and a
±3%/2mm global criterion was 90.1% and 90.8% for FFF 6MV and FFF 10MV source models,
respectively.
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Chapter 5: Robustness Study at Outside Institutions: Elekta and Varian TrueBeam FFF
6MV and 10MV
5.1 Introduction
The Radiological Physics Center (RPC) has published the results for its anthropomorphic
phantom audit program showing varying degrees of success amongst institutions[13, 17].
There is reason to believe that one potential source of discrepancy between these
measurement to calculated dose comparisons is the accuracy of the dose calculations
algorithms in heterogeneous media[12, 18]. Previously, the RPC has been unable to verify the
accuracy of this step in the radiation therapy treatment process[19]. In order to ensure a higher
degree of consistency among institutions participating in National Cancer Institute (NCI) funded
clinical trials and improve upon patient safety, the RPC began the development of an
independent dose calculation tool to be used in the auditing process[20, 21, 35].
In its current state, the dose calculation tool includes models of Varian 6MV and 10MV
therapeutic linear accelerators. Chapters 3 and 4 detailed the inclusion of Elekta 6MV and
10MV models and Varian TrueBeam FFF 6MV and FFF 10MV models, respectively. The
addition of these four models were intended to cover the majority of the approximately 25% of
monitored beams not modeled by the dose calculation tool. In order to be truly useful as an
auditing tool, the models must be able to accurately predict dose distributions for all linear
accelerators of a common manufacturer and not just the linear accelerator whose dosimetry
data was used during commissioning of the models. RPC collected dosimetry data suggests
that this is possible as over 90% of all beams from a common manufacturer have shown
agreement within ±2%[55].

5.2 Materials and Methods
The RPC conducts their phantom audits through a comparison of TLD measurement and
film measurement to institution submitted calculated dosimetry data. The measurement data
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from the phantom irradiation along with the institution submitted treatment plan data and
calculated doses are archived with the auditing report sent to the institution. While it is not
required for the audit, if the treatment plan data contains the plan information contained within
the DICOM RT plan (RP) file, this archived plan file can be used as input to the Monte Carlo
models described in Chapters 2-4. This provides all the necessary information to run a
comparison between Monte Carlo calculated doses and phantom measurements similar to the
model benchmarking performed in Chapter 3 Section 3 and Chapter 4 Section 3.
To evaluate the models performance against measurements on beams not used in the
commissioning of the model, a comparison between Monte Carlo calculated dose and
measurement dose from past phantom audits will be performed. Audits chosen for the
comparison will be selected based on three criteria.
First, the phantom audit must have passed the RPC’s criteria. For the IMRT head and neck
phantom this requires TLD measurements to be within ±7% of the predicted calculated dose
and gamma agreement to be >85% at a ±7%/4mm criterion. For the lung phantom the TLD
measurements must be within ±5% of a measured to calculated dose ratio of 0.97 for
deterministic dose calculation algorithms and ±5% of a ratio of 1.00 for Monte Carlo dose
calculation algorithms. An analysis of past audits on the lung phantom has shown a systematic
disagreement between measurement and deterministic calculations of 3-4%[72]. By requiring
the measurement to be within ±5% of a ratio of 0.97 the systematic offset is accounted for in
comparisons to doses calculated by deterministic algorithms. Additionally, the gamma analysis
of the film measurement compared to dose calculation must be in agreement for >85% of data
tested with a ±5%/5mm criterion.
The RPC’s phantoms act as an end to end test of the treatment process. The AAPM Task
Group Report Number 85 breaks down the acceptable uncertainties of the entire treatment
process, of which the dose calculations are a small part[73]. For this reason, the past phantom
audits to be compared to the tool must show agreement between measurement and calculated
data superior to the minimum requirements for passing the audit. Preference will be given to
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audits with TLD measurements within ±3% of the predicted calculated dose. For the lung
phantom audits, the ±3% acceptance criteria will be centered on a measured to calculated
dose ratio of 0.97 for doses calculated by deterministic algorithms. To minimize the impact of
measurement uncertainty caused by collecting data from phantoms irradiated by outside
institutions, comparisons will be restricted to the TLD contained in the PTV for both phantoms.
The final assessment for selection of the phantom audit will be based on a comparison of
the dose profile agreement included in the institution’s audit report. This will be a subjective
evaluation of the dose distribution shape and phantom alignment. While offsets within ±3mm in
the phantom positioning can be accounted for in the registration of the calculated dose to the
film measurements, accounting for larger offsets would increase the uncertainty in the
comparison to unacceptable levels. While some offsets can be accounted for, a delivery error
resulting in a different dose distribution cannot be accurately predicted to input into the multiple
source model calculation. While this change may not affect the passing rate using a ±7%/4mm
or ±5%/5mm gamma criterion in the phantom audit, it will likely cause failure at the more
restrictive ±3%/2mm criterion that has been used on the benchmarking studies of the model.
Table 5.1 and Table 5.2 report the phantom audits chosen for the comparison of multiple
source model calculations to past measurements for head and neck phantoms and lung
phantoms, respectively. Because FFF is relatively new delivery technique and 10MV beams
are less common than 6MV beams, there were no TrueBeam FFF 10MV phantom audits.
Likewise, only the lung phantom has been used for auditing TrueBeam FFF 6MV beams. The
use of Elekta 10MV beams is also uncommon among RPC audited institutions. There were no
Elekta 10MV phantom audits that met the selection criteria.
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Delivery
H&N Plan
#1
H&N Plan
#2

Manufacturer

Model

Energy
(MV)

Technique

TPS

Elekta

Synergy

6MV

SMLC

Pinnacle

Elekta

Agility S

6MV

SMLC

Pinnacle

Table 5.1: Summary of head and neck phantom audits chosen for a measurement based
comparison to Monte Carlo recalculation of plan dose. Both plans were step and shoot IMRT,
or static MLC (SMLC), deliveries.

Delivery
Lung Plan
#1
Lung Plan
#2
Lung Plan
#3

Manufacturer

Model

Energy
(MV)

Technique

TPS

Varian

TrueBeam 6MV FFF

3D

Pinnacle

Varian

TrueBeam 6MV FFF

3D

Pinnacle

Elekta

Synergy

SMLC

Pinnacle

6MV

Table 5.2: Summary of lung phantom audits chosen for a measurement based comparison to
Monte Carlo recalculation of plan dose. Delivery techniques were either 3D or static MLC
(SMLC).

5.3 Results
5.3.1 Point Dose Comparison
The results to the point dose comparisons for the past audit study are reported in Table 5.3
for head and neck phantom audits. The recalculation of doses for the head and neck audits
resulted in an average calculated to measured TLD dose ratio in the PTV of 1.019. The
institution reported TLD doses as determined by the TPS yielded an average agreement of
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1.020 in the PTV. The mean agreement of the two calculated doses was not significant
according to a paired t-test (p=0.9293). The range of agreement in the PTV for the multiple
source model recalculated doses was 1.005 to 1.030. The corresponding range for TPS
agreement was 0.991 to 1.050.

Delivery
H&N Plan
#1
H&N Plan
#2

PTV TLD SA
TPS
DPM

PTV TLD IA
TPS DPM

PTV TLD SP
TPS DPM

PTV TLD IP
TPS DPM

PTV TLD Avg.
TPS
DPM

1.003

1.005 1.015 1.027 0.991 1.019 1.010 1.027 1.005

1.020

1.040

1.015 1.050 1.028 1.019 1.003 1.031 1.030 1.035

1.019

Table 5.3: Point dose comparisons for the multiple source model recalculation of the head and
neck phantom audits. Comparison to calculated doses by DPM and the institution reported
doses calculated by the TPS are expressed as a ratio of calculated to measured doses. Point
dose locations were restricted to within the PTV. S = Superior, I = Inferior, A = Anterior, P =
Posterior.

The results to the point dose comparisons for the past lung phantom audit study is reported
in Table 5.4. The averaged ratio of DPM recalculated dose to measurement was 0.986
compared to 1.023 for institution submitted doses calculated by the TPS. The mean agreement
was determined to be significant using a paired t-test (p=0.0004). Using the same statistical
analysis, the difference from 1.000 was not shown to be significantly better for the DPM
recalculated doses with respect to the TPS calculated doses (p=0.3276). The range of the
agreement for recalculated doses was 0.975 to 0.995. The range of the ratio of TPS calculated
doses to measurement was 1.007 to 1.042.
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Delivery
Lung Plan #1
Lung Plan #2
Lung Plan #3

PTV TLD S
TPS
1.021
1.007
1.038

DPM
0.994
0.975
0.988

PTV TLD I
TPS
1.013
1.015
1.042

DPM
0.989
0.978
0.995

PTV TLD Avg.
TPS
1.017
1.011
1.040

DPM
0.991
0.977
0.992

Table 5.4: Point dose comparisons for the multiple source model recalculation of the lung
phantom audits. Comparison to calculated doses by DPM and the institution reported doses
calculated by the TPS are expressed as a ratio of calculated to measured doses. Point dose
locations were restricted to within the PTV. S = Superior, I = Inferior.

5.3.2 Gamma Map Comparison
To compare the multiple source models’ accuracy in modeling the beam penumbra, MLC
leaf tips, MLC transmission, and MLC leakage for outside institution beams, agreement
between DPM recalculated doses and archived film measurements were evaluated using the
gamma technique[68]. The analysis considers dose differences as relative percentage and the
distance to agreement to assess overall agreement and identify locations of difficulty to the
model. The analysis was performed with ±3%/2mm and ±5%/3mm criteria. All film
measurements were also compared to the TPS calculated dose submitted by the audited
institution using the same technique and criteria. The results of the comparisons are reported in
Table 5.5 and Table 5.6 for head and neck audits using ±3%/2mm and ±5%/3mm criteria,
respectively. Table 5.7 and Table 5.8 report the agreement for the lung audits using ±3%/2mm
and ±5%/3mm criteria, respectively. The corresponding gamma maps for each comparison at
each criterion are presented in the Appendix (Chapter 7).
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Delivery
H&N Plan
#1
H&N Plan
#2

DPM

TPS

Axial

Sagittal

Axial

Sagittal

59.1

69.4

67.6

75.3

88.4

52.5

85.9

69.8

Table 5.5: Percentages of pixels passing a ±3%/2mm gamma criterion for previous head and
neck audits are reported. Agreement was evaluated in the axial and sagittal planes.

Delivery
H&N Plan
#1
H&N Plan
#2

DPM

TPS

Axial

Sagittal

Axial

Sagittal

82.1

88.2

88.6

98.9

98.3

76.8

98.4

86.3

Table 5.6: Percentages of pixels passing a ±5%/3mm gamma criterion for previous head and
neck audits are reported. Agreement was evaluated in the axial and sagittal planes.

Delivery
Lung Plan
#1
Lung Plan
#2
Lung Plan
#3

DPM

TPS

Axial Coronal Sagittal Axial Coronal Sagittal
99.7

99.0

94.9

97.4

95.5

86.8

88.4

79.1

82.6

96.0

93.3

66.8

92.1

92.6

97.1

64.1

53.6

64.1

Table 5.7: Percentages of pixels passing a ±3%/2mm gamma criterion for previous lung audits
are reported. Agreement was evaluated in the axial, coronal and sagittal planes.
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Delivery
Lung Plan
#1
Lung Plan
#2
Lung Plan
#3

DPM

TPS

Axial Coronal Sagittal Axial Coronal Sagittal
99.9

99.0

99.6

99.9

99.9

99.4

99.0

96.9

99.5

99.9

99.8

93.2

99.1

99.6

99.8

85.7

82.5

82.4

Table 5.8: Percentages of pixels passing a ±5%/3mm gamma criterion for previous lung audits
are reported. Agreement was evaluated in the axial, coronal and sagittal planes.

The average agreement in the head and neck phantom audits using a ±3%/2mm gamma
criterion was 67.3% and 74.7% for DPM recalculated doses and TPS calculated doses,
respectively. At a less restrictive ±5%/3mm criterion the average agreement was 86.3% and
93.0% for the DPM recalculated doses and TPS calculated doses, respectively. Among the four
film comparison (2 axial, 2 sagittal), TPS calculated doses showed better agreement in three
comparisons at the ±3%/2mm criterion and all four comparisons at the ±5%/3mm criterion.
The average agreement in the lung phantom audits using a ±3%/2mm gamma criterion was
91.7% and 79.7% for DPM recalculated doses and TPS calculated doses, respectively. Using a
±5%/3mm criterion the average agreement was 99.2% and 93.6% for DPM recalculated doses
and TPS calculated doses, respectively. Among the nine film comparisons (3 axial, 3 coronal, 3
sagittal), the DPM recalculate doses showed superior agreement in seven comparisons at the
±3%/2mm criterion and five comparisons at a ±5%/3mm criterion.
Due to the low number of phantom audits meeting the recalculation selection criteria, it is
difficult to establish significance or meaning behind the discrepancy in performance for DPM
recalculated doses and TPS calculated doses. The superior agreement in the lung phantom
audits can likely be explained by the superior accuracy in radiation transport utilizing the Monte
Carlo technique compared to deterministic algorithms. It is possible that the inferior
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performance of the multiple source models in the head and neck phantom audits could be due
to poorer leaf modeling by the calculation tool. The head and neck phantoms require more
modulation to achieve the planning criteria compared to the lung phantoms. The increased
modulation could compound the effects of small differences in modeling techniques.

5.4 Conclusion
The multiple source models developed for the RPC’s dose calculation quality assurance tool
have been used to recalculate doses to the RPC’s anthropomorphic phantoms from previous
credentialing audits. By using archived CT data sets, DICOM RT plan files, and TLD and film
measurements, the models’ performance could be assessed against outside institution
measurements and against the performance of commercial treatment planning systems. This
assessment was done for five previous credentialing audits consisting of two head and neck
phantom audits and three lung phantom audits. Audits were chosen based on the availability of
the necessary archived data and superior performance in the credentialing process.
Point dose comparisons using the enclosed TLD capsules in the head and neck phantoms
showed an average calculated to measurement ratio of 1.019 and 1.020 for DPM recalculated
doses and TPS calculated doses, respectively. Comparisons in the lung phantoms showed an
average calculated to measurement ratio of 0.986 and 1.023 for DPM recalculated doses and
TPS calculated doses, respectively. Differences in the head and neck phantom were not
significant, and while significantly different in the lung phantoms, the performance was not
significantly better for either calculation method.
To assess the ability of the two dose calculation methods’ ability to predict complex dose
distributions in both homogenous and heterogeneous media, a comparison of film
measurement to calculated dose was performed for both phantoms using the gamma
technique. At a ±3%/2mm criterion the average agreement for DPM recalculated dose was
67.3% and 91.7% for head and neck phantoms and lung phantoms, respectively. The TPS
calculated dose showed average agreements for the same gamma criterion of 74.7% and
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79.7% for head and neck phantoms and lung phantoms, respectively. Differences in
performance suspected to be attributable to superior accuracy in transport in heterogeneous
media for the Monte Carlo technique and more accurate leaf modeling by the TPS. More
comparisons between DPM recalculated dose and TPS calculated dose are needed fully
assess these differences.
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Chapter 6: Summary
6.1 Summary for Elekta Models
Multiple source models for Elekta 6MV and 10MV beams were developed (Chapter 3) in a
two-step commissioning process. First energy spectra were optimized by a comparison of
central axis depth dose data in water for Monte Carlo calculated dose and measured dose.
Next off-axis effects were accounted for in matching Monte Carlo calculated dose profiles to
measured dose profiles for a 40 x 40 cm2 field size. The commissioned models were then
validated against open field measurements consisting of depth dose curves and dose profiles
at field sizes from 3 x 3 cm 2 to 30 x 30 cm2. Agreement was evaluated using the gamma
technique and a criterion of ±2% of the maximum dose and ±2mm distance to agreement. All
depth dose and dose profile comparisons exceeded 90% of data passing the criterion.
The multiple source models were then benchmarked against clinically realistic treatment
deliveries using measurements from anthropomorphic phantoms. Treatments consisted of an
IMRT head and neck plan, a 3D conformal SBRT lung plan, and an IMRT lung plan.
Measurements from TLD and film were used to compare the models’ performance to
measurement. Agreement for dose distributions measured by the film was assessed using the
gamma technique and a ±3% of the maximum dose and ±2mm distance to agreement criterion.
All film planes for each treatment delivery averaged over 85% of data passing the established
criterion.

6.2 Summary for Varian TrueBeam FFF Models
Multiple source models for Varian TrueBeam FFF 6MV and FFF 10MV beams were
developed (Chapter 4) in a two-step commissioning process. First the energy spectra were
determined from an optimization process based on a comparison of Monte Carlo calculated
central axis depth dose data to measured central axis depth dose data. Next the off-axis effects
were accounted for by matching calculated dose profiles measured dose profiles for a 40 x 40
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cm2 field size. The models were then validated against open field measurements in a water
tank at field sizes from 3 x 3 cm 2 to 40 x 40 cm2. Agreement between calculation and
measurement was assessed using the gamma technique and a criterion of ±2% of the
maximum dose and ±2mm distance to agreement. All depth dose and dose profile comparisons
exceeded 88% of the data passing the criterion.
The developed source models were then benchmarked against clinically realistic treatment
deliveries using anthropomorphic phantoms. The treatment plans designed to increasingly
challenge the models and consisted of an IMRT head and neck delivery, a 3D conformal SBRT
lung delivery, and an IMRT lung delivery. Performance of the model was assessed through a
comparison of dose calculations to TLD measurement and film measurement. Dose distribution
agreement was assessed in the film comparison using the gamma technique and a ±3% of the
maximum dose and ±2mm distance to agreement criterion. All film planes from all deliveries
averaged over 85% of data passing the criterion.

6.3 Summary for Robustness Study
To evaluate the robustness of the multiple source models developed in Chapter 3 and
Chapter 4 and their feasibility for use in a dose calculation quality assurance audit tool, a
retrospective analysis of recalculated dose with respect to measurement was performed on
archived credentialing audits (Chapter 5). Phantom audits that were performed on therapeutic
x-ray beams fitting the description of the models and with superior performance on the audit
were chosen for analysis. Selected audits for comparison consisted of both lung phantom
deliveries and head and neck phantom deliveries. Archived DICOM RT files were used to
recalculate the phantom dose using the multiple source models and performance was
evaluated by comparing to archived measurements from the audit. Performance of the multiple
source model comparisons was then compared to performance of the treatment planning
system calculated dose.
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Point dose comparisons using the calculated dose to TLD measured dose ratio from the
head and neck phantoms showed comparable performance for the DPM recalculated dose,
1.019, with respect to the TPS calculated dose, 1.020. Dose distribution comparisons of
calculated dose to film measurements evaluated using the gamma technique and a ±3% of the
maximum dose and ±2mm distance to agreement showed superior performance from the TPS
calculations, 74.7% of data passing, compared to the DPM recalculated dose, 67.3% of data
passing.
Point dose comparisons using the calculated dose to TLD measured dose ratio from the
lung phantoms showed statistically significant differences between DPM recalculated dose,
0.986 and TPS calculated dose, 1.023. Accuracy, however, was not significant. The dose
distributions were evaluated using film measurement and the gamma technique with a ±3% of
the maximum dose and ±2mm distance to agreement criterion. The average percent of pixels
passing was higher in the DPM recalculated dose, 91.7%, compared to the TPS calculated
dose, 79.7%.

6.4 Evaluation of the Hypothesis
The hypothesis to the project was that Monte Carlo, multiple source models of Elekta 6MV,
Elekta 10MV, Varian TrueBeam FFF 6MV, and Varian TrueBeam FFF 10MV beams could be
developed based on measurements to an accuracy of ±3% of the maximum dose and ±2mm
distance to agreement in anthropomorphic phantom measurements.
The development and validation of the source models (Specific Aim #1) is documented in
Chapter 3 (Elekta) and Chapter 4 (Varian TrueBeam FFF). This needed to be done at an
accuracy of ±2% of the maximum dose and ±2mm distance to agreement compared to open
field, water tank measurements.
They hypothesis was then evaluated in benchmark testing performed against
anthropomorphic phantoms. The conditions under which the hypothesis was tested are outlined
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in Specific Aim #2 and Chapter 3 (Elekta) and Chapter 4 (Varian TrueBeam FFF). The
treatment plans for the phantoms were designed to present increasingly challenging dose
calculation conditions and consisted of an IMRT head and neck plan, a 3D conformal SBRT
lung plan, and an IMRT lung plan. Reported average agreement for all four multiple source
models in each plane of evaluation for all treatment plans exceeded 85%. The results of the
benchmark testing proved the hypothesis true.

6.5 General Conclusions
Development of an independent, dose calculation, quality assurance tool for clinical trial
audits was completed through the addition of multiple source models of Elekta 6MV and 10MV
and Varian TrueBeam FFF 6MV and FFF 10MV beams to the already developed Varian 6MV
and 10MV models. The new models were validated against water tank measurements for open
fields with excellent agreement. The models then met the benchmarking criteria established to
show a high degree of accuracy in clinically realistic treatment plans delivered to
anthropomorphic phantoms. These treatment plans consisted of modulated and un-modulated
plans delivered to homogeneous and heterogeneous media. As a proof of concept of the tool’s
utility in this role, a retrospective analysis of past phantom credentialing audits was performed
with the dose calculation tool. The excellent agreement in the benchmarking studies and
successful use in a retrospective study suggest that the tool is ready for implementation in the
RPC’s quality assurance program.

6.6 Future Work
The addition of Elekta 6MV and 10MV and Varian TrueBeam FFF 6MV and FFF 10MV
beams to the previously existing Varian 6MV and 10MV models makes the independent dose
calculation quality assurance tool developed useful for auditing purposes. Deficiencies in the
models’ benchmarking and ability to handle some treatment techniques still exist. To date,
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models have only been benchmarked against step and shoot technique for IMRT deliveries.
While adaptation to a sliding window technique will not fundamentally change the way the
model calculates dose, the models should be benchmarked to confirm this. A more significant
modification of the model will be needed to account for volumetric arc therapy (VMAT)
deliveries. These have become increasingly popular treatment techniques and due to the way
in which the model breaks the calculations down by beam and samples particle origin by
fluence segments, VMAT deliveries cannot not be currently handled by the tool. Inclusion of
this technique will require a modification to the sampling done in particle generation.
With a functioning dose calculation tool it will also be increasingly important that institutions
submit DICOM RT plan files as a part of phantom audits. This is necessary if the dose
calculations submitted by institutions are to be checked and will allow for larger scale data
collection in comparing the performance of specific dose calculation algorithms to the dose
calculation tool. Chapter 5 suffered from a lack of data points caused largely by a lack of
archived audits containing DICOM RT plan information needed for the dose calculations.

155

Chapter 7: Appendix
7.1 Elekta 6 MV: Percent Depth Dose and Dose Profiles

Figure 7.1: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an
Elekta 6MV beam at a field size of 3 x 3 cm2. Gamma agreement (red circles) for each point is
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion. At this field size 99.43% of all data passed the gamma criterion.
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Figure 7.2: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an
Elekta 6MV beam at a field size of 5 x 5 cm2. Gamma agreement (red circles) for each point is
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion. At this field size 99.43% of all data passed the gamma criterion.

Figure 7.3: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an
Elekta 6MV beam at a field size of 10 x 10 cm2. Gamma agreement (red circles) for each point
is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion. At this field size 100% of all data passed the gamma criterion.
157

Figure 7.4: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an
Elekta 6MV beam at a field size of 15 x 15 cm2. Gamma agreement (red circles) for each point
is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion. At this field size 100% of all data passed the gamma criterion.

Figure 7.5: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an
Elekta 6MV beam at a field size of 20 x 20 cm2. Gamma agreement (red circles) for each point
is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion. At this field size 99.43% of all data passed the gamma criterion.
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Figure 7.6: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an
Elekta 6MV beam at a field size of 30 x 30 cm2. Gamma agreement (red circles) for each point
is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion. At this field size 99.43% of all data passed the gamma criterion.
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Figure 7.7: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 6MV
beam at a field size of 3 x 3 cm2.

Field Size (cm2)

Direction Depth (cm)

% Passing (2%/2mm)

x

1.6

95.00

x

5

100.00

x

10

100.00

x

20

100.00

y

1.6

97.14

y

5

100.00

y

10

100.00

y

20

100.00

3x3

Table 7.1: Dose profile agreement between the Elekta 6MV multiple source model and
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 3 x 3
cm2 field size.
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Figure 7.8: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 6MV
beam at a field size of 5 x 5 cm2.

Field Size (cm2)

Direction Depth (cm)

% Passing (2%/2mm)

x

1.6

98.04

x

5

100.00

x

10

100.00

x

20

100.00

y

1.6

97.92

y

5

100.00

y

10

100.00

y

20

100.00

5x5

Table 7.2: Dose profile agreement between the Elekta 6MV multiple source model and
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 5 x 5
cm2 field size.
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Figure 7.9: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta 6MV
beam at a field size of 10 x 10 cm2.
Field Size (cm2)

Direction Depth (cm)

% Passing (2%/2mm)

x

1.6

96.34

x

5

100.00

x

10

100.00

x

20

100.00

y

1.6

100.00

y

5

100.00

y

10

100.00

y

20

100.00

10 x 10

Table 7.3: Dose profile agreement between the Elekta 6MV multiple source model and
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 10 x
10 cm2 field size.
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Figure 7.10: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta
6MV beam at a field size of 15 x 15 cm2.
Field Size (cm2)

Direction Depth (cm)

% Passing (2%/2mm)

x

1.6

94.78

x

5

100.00

x

10

100.00

x

20

100.00

y

1.6

100.00

y

5

100.00

y

10

100.00

y

20

100.00

15 x 15

Table 7.4: Dose profile agreement between the Elekta 6MV multiple source model and
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 15 x
15 cm2 field size.
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Figure 7.11: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta
6MV beam at a field size of 20 x 20 cm2.
Field Size (cm2)

Direction Depth (cm)

% Passing (2%/2mm)

x

1.6

98.68

x

5

99.51

x

10

100.00

x

20

100.00

y

1.6

97.98

y

5

100.00

y

10

99.51

y

20

100.00

20 x 20

Table 7.5: Dose profile agreement between the Elekta 6MV multiple source model and
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 20 x
20 cm2 field size.
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Figure 7.12: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta
6MV beam at a field size of 30 x 30 cm2.
Field Size (cm2)

Direction Depth (cm)

% Passing (2%/2mm)

x

1.6

98.50

x

5

99.51

x

10

100.00

x

20

100.00

y

1.6

97.98

y

5

100.00

y

10

99.51

y

20

100.00

30 x 30

Table 7.6: Dose profile agreement between the Elekta 6MV multiple source model and
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 30 x
30 cm2 field size.
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7.2 Elekta 6 MV: Gamma Maps
7.2.1 Elekta 6 MV: Delivery of IMRT Head and Neck Plan

Figure 7.13: IMRT head and neck delivery comparison for the axial plane of delivery #2 for the
Elekta 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 87.6% of
pixels passed.
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Figure 7.14: IMRT head and neck delivery comparison for the sagittal plane of delivery #2 for
the Elekta 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
86.7% of pixels passed.

Figure 7.15: IMRT head and neck delivery comparison for the axial plane of delivery #3 for the
Elekta 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 82.5% of
pixels passed.
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Figure 7.16: IMRT head and neck delivery comparison for the sagittal plane of delivery #3 for
the Elekta 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
86.1% of pixels passed.
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7.2.2 Elekta 6 MV: Delivery of SBRT Lung Plan

Figure 7.17: Lung SBRT delivery comparison for the axial plane of delivery #2 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 86.2% of pixels
passed.
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Figure 7.18: Lung SBRT delivery comparison for the sagittal plane of delivery #2 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 85.3% of pixels
passed.

Figure 7.19: Lung SBRT delivery comparison for the coronal plane of delivery #2 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 85.9% of pixels
passed.
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Figure 7.20: Lung SBRT delivery comparison for the axial plane of delivery #3 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 89.0% of pixels
passed.

Figure 7.21: Lung SBRT delivery comparison for the sagittal plane of delivery #3 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 84.2% of pixels
passed.
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Figure 7.22: Lung SBRT delivery comparison for the coronal plane of delivery #3 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 88.1% of pixels
passed.
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7.2.3 Elekta 6 MV: Delivery of IMRT Lung Plan

Figure 7.23: Lung IMRT delivery comparison for the axial plane of delivery #1 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 82.6% of pixels
passed.
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Figure 7.24: Lung IMRT delivery comparison for the sagittal plane of delivery #1 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 92.5% of pixels
passed.

Figure 7.25: Lung IMRT delivery comparison for the coronal plane of delivery #1 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 89.8% of pixels
passed.
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Figure 7.26: Lung IMRT delivery comparison for the axial plane of delivery #2 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 85.4% of pixels
passed.

Figure 7.27: Lung IMRT delivery comparison for the sagittal plane of delivery #2 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 83.5% of pixels
passed.
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Figure 7.28: Lung IMRT delivery comparison for the coronal plane of delivery #2 for the Elekta
6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 89.8% of pixels
passed.
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7.3 Elekta 10 MV: Percent Depth Dose and Dose Profiles

Figure 7.29: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an
Elekta 10MV beam at a field size of 3 x 3 cm2. Gamma agreement (red circles) for each point is
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion. At this field size 99.43% of all data passed the gamma criterion.
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Figure 7.30: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an
Elekta 10MV beam at a field size of 5 x 5 cm2. Gamma agreement (red circles) for each point is
also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion. At this field size 99.43% of all data passed the gamma criterion.

Figure 7.31: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an
Elekta 10MV beam at a field size of 10 x 10 cm2. Gamma agreement (red circles) for each point
is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion. At this field size 99.43% of all data passed the gamma criterion.
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Figure 7.32: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an
Elekta 10MV beam at a field size of 15 x 15 cm2. Gamma agreement (red circles) for each point
is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion. At this field size 100% of all data passed the gamma criterion.

Figure 7.33: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an
Elekta 10MV beam at a field size of 20 x 20 cm2. Gamma agreement (red circles) for each point
is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion. At this field size 100% of all data passed the gamma criterion.
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Figure 7.34: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for an
Elekta 10MV beam at a field size of 30 x 30 cm2. Gamma agreement (red circles) for each point
is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion. At this field size 100% of all data passed the gamma criterion.
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Figure 7.35: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta
10MV beam at a field size of 3 x 3 cm2.

Field Size (cm2)

Direction Depth (cm)

% Passing (2%/2mm)

x

1.6

95.65

x

5

100.00

x

10

100.00

x

20

100.00

x

25

100.00

y

1.6

100.00

y

5

100.00

y

10

100.00

y

20

100.00

y

25

100.00

3x3

Table 7.7: Dose profile agreement between the Elekta 10MV multiple source model and
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 3 x 3
cm2 field size.
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Figure 7.36: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta
10MV beam at a field size of 5 x 5 cm2.
Field Size (cm2)

Direction Depth (cm)

% Passing (2%/2mm)

x

1.6

100.00

x

5

100.00

x

10

100.00

x

20

100.00

x

25

100.00

y

1.6

100.00

y

5

100.00

y

10

100.00

y

20

100.00

y

25

100.00

5x5

Table 7.8: Dose profile agreement between the Elekta 10MV multiple source model and
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 5 x 5
cm2 field size.
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Figure 7.37: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta
10MV beam at a field size of 10 x 10 cm2.

Field Size (cm2)

Direction Depth (cm)

% Passing (2%/2mm)

x

1.6

100.00

x

5

100.00

x

10

100.00

x

20

100.00

x

25

100.00

y

1.6

100.00

y

5

100.00

y

10

100.00

y

20

100.00

y

25

100.00

10 x 10

Table 7.9: Dose profile agreement between the Elekta 10MV multiple source model and
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 10 x
10 cm2 field size.
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Figure 7.38: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta
10MV beam at a field size of 15 x 15 cm2.
Field Size (cm2)

Direction Depth (cm)

% Passing (2%/2mm)

x

1.6

94.95

x

5

100.00

x

10

100.00

x

20

100.00

x

25

100.00

y

1.6

100.00

y

5

100.00

y

10

100.00

y

20

100.00

y

25

100.00

15 x 15

Table 7.10: Dose profile agreement between the Elekta 10MV multiple source model and
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 15 x
15 cm2 field size.
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Figure 7.39: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta
10MV beam at a field size of 20 x 20 cm2.
Field Size (cm2)

Direction Depth (cm)

% Passing (2%/2mm)

x

1.6

90.98

x

5

98.51

x

10

100.00

x

20

100.00

x

25

100.00

y

1.6

99.19

y

5

100.00

y

10

100.00

y

20

100.00

y

25

100.00

20 x 20

Table 7.11: Dose profile agreement between the Elekta 10MV multiple source model and
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 20 x
20 cm2 field size.
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Figure 7.40: Calculated (red diamond) and measured (blue line) dose profiles for an Elekta
10MV beam at a field size of 30 x 30 cm2.
Field Size (cm2)

Direction Depth (cm)

% Passing (2%/2mm)

x

1.6

98.97

x

5

100.00

x

10

100.00

x

20

100.00

x

25

100.00

y

1.6

99.45

y

5

100.00

y

10

100.00

y

20

100.00

y

25

100.00

30 x 30

Table 7.12: Dose profile agreement between the Elekta 10MV multiple source model and
measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 30 x
30 cm2 field size.
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7.4 Elekta 10 MV: Gamma Maps
7.4.1 Elekta 10 MV: Delivery of IMRT Head and Neck Plan

Figure 7.41: IMRT head and neck delivery comparison for the axial plane of delivery #2 for the
Elekta 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 91.6%
of pixels passed.
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Figure 7.42: IMRT head and neck delivery comparison for the sagittal plane of delivery #2 for
the Elekta 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
86.4% of pixels passed.

Figure 7.43: IMRT head and neck delivery comparison for the axial plane of delivery #3 for the
Elekta 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 95.9%
of pixels passed.
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Figure 7.44: IMRT head and neck delivery comparison for the sagittal plane of delivery #3 for
the Elekta 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
87.3% of pixels passed.
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7.4.2 Elekta 10 MV: Delivery of SBRT Lung Plan

Figure 7.45: Lung SBRT delivery comparison for the axial plane of delivery #2 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 86.2% of
pixels passed.
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Figure 7.46: Lung SBRT delivery comparison for the sagittal plane of delivery #2 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 90.8% of
pixels passed.

Figure 7.47: Lung SBRT delivery comparison for the coronal plane of delivery #2 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 85.3% of
pixels passed.
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Figure 7.48: Lung SBRT delivery comparison for the axial plane of delivery #3 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 88.1% of
pixels passed.

Figure 7.49: Lung SBRT delivery comparison for the sagittal plane of delivery #3 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 85.2% of
pixels passed.
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Figure 7.50: Lung SBRT delivery comparison for the coronal plane of delivery #3 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 90.5% of
pixels passed.
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7.4.3 Elekta 10 MV: Delivery of IMRT Lung Plan

Figure 7.51: Lung IMRT delivery comparison for the axial plane of delivery #2 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 85.8% of
pixels passed.
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Figure 7.52: Lung IMRT delivery comparison for the sagittal plane of delivery #2 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 87.3% of
pixels passed.

Figure 7.53: Lung IMRT delivery comparison for the coronal plane of delivery #2 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 89.3% of
pixels passed.
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Figure 7.54: Lung IMRT delivery comparison for the axial plane of delivery #3 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 92.5% of
pixels passed.

Figure 7.55: Lung IMRT delivery comparison for the sagittal plane of delivery #3 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 94.0% of
pixels passed.
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Figure 7.56: Lung IMRT delivery comparison for the coronal plane of delivery #3 for the Elekta
10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and 88.5% of
pixels passed.
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7.5 Varian TrueBeam 6 MV: Percent Depth Dose and Dose Profiles

Figure 7.57: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a
TrueBeam FFF 6MV beam at a field size of 3 x 3 cm2. Gamma agreement (red circles) for each
point is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion. At this field size 100.0% of all data passed the gamma criterion.

Figure 7.58: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a
TrueBeam FFF 6MV beam at a field size of 4 x 4 cm2. Gamma agreement (red circles) for each
point is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion. At this field size 100.0% of all data passed the gamma criterion.
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Figure 7.59: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a
TrueBeam FFF 6MV beam at a field size of 6 x 6 cm2. Gamma agreement (red circles) for each
point is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion. At this field size 99.33% of all data passed the gamma criterion.

Figure 7.60: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a
TrueBeam FFF 6MV beam at a field size of 8 x 8 cm2. Gamma agreement (red circles) for each
point is also displayed along with any points (red star) at which a failure to meet the ±2%/2mm
criterion. At this field size 100.0% of all data passed the gamma criterion.
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Figure 7.61: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a
TrueBeam FFF 6MV beam at a field size of 10 x 10 cm2. Gamma agreement (red circles) for
each point is also displayed along with any points (red star) at which a failure to meet the
±2%/2mm criterion. At this field size 100.0% of all data passed the gamma criterion.

Figure 7.62: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a
TrueBeam FFF 6MV beam at a field size of 20 x 20 cm2. Gamma agreement (red circles) for
each point is also displayed along with any points (red star) at which a failure to meet the
±2%/2mm criterion. At this field size 100.0% of all data passed the gamma criterion.
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Figure 7.63: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a
TrueBeam FFF 6MV beam at a field size of 30 x 30 cm2. Gamma agreement (red circles) for
each point is also displayed along with any points (red star) at which a failure to meet the
±2%/2mm criterion. At this field size 100.0% of all data passed the gamma criterion.

Figure 7.64: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a
TrueBeam FFF 6MV beam at a field size of 40 x 40 cm2. Gamma agreement (red circles) for
each point is also displayed along with any points (red star) at which a failure to meet the
±2%/2mm criterion. At this field size 100.0% of all data passed the gamma criterion.
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Figure 7.65: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
6MV beam at a field size of 3 x 3 cm2.

Field Size (cm2)

3x3

Direction Depth (cm)

% Passing (2%/2mm)

x

1.5

98.45

x

5

98.45

x

10

100.00

x

20

100.00

x

30

100.00

Table 7.13: Dose profile agreement between the TrueBeam FFF 6MV multiple source model
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 3
x 3 cm2 field size.
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Figure 7.66: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
6MV beam at a field size of 4 x 4 cm2.

Field Size (cm2)

4x4

Direction Depth (cm)

% Passing (2%/2mm)

x

1.5

96.45

x

5

98.58

x

10

100.00

x

20

100.00

x

30

100.00

Table 7.14: Dose profile agreement between the TrueBeam FFF 6MV multiple source model
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 4
x 4 cm2 field size.
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Figure 7.67: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
6MV beam at a field size of 6 x 6 cm2.

Field Size (cm2)

6x6

Direction Depth (cm)

% Passing (2%/2mm)

x

1.5

98.76

x

5

99.34

x

10

100.00

x

20

100.00

x

30

100.00

Table 7.15: Dose profile agreement between the TrueBeam FFF 6MV multiple source model
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 6
x 6 cm2 field size.
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Figure 7.68: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
6MV beam at a field size of 8 x 8 cm2.

Field Size (cm2)

8x8

Direction Depth (cm)

% Passing (2%/2mm)

x

1.5

96.13

x

5

100.00

x

10

100.00

x

20

100.00

x

30

100.00

Table 7.16: Dose profile agreement between the TrueBeam FFF 6MV multiple source model
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 8
x 8 cm2 field size.
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Figure 7.69: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
6MV beam at a field size of 10 x 10 cm2.

Field Size (cm2)

10 x 10

Direction Depth (cm)

% Passing (2%/2mm)

x

1.5

93.97

x

5

99.50

x

10

100.00

x

20

100.00

x

30

100.00

Table 7.17: Dose profile agreement between the TrueBeam FFF 6MV multiple source model
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a
10 x 10 cm2 field size.
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Figure 7.70: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
6MV beam at a field size of 20 x 20 cm2.

Field Size (cm2)

20 x 20

Direction Depth (cm)

% Passing (2%/2mm)

x

1.5

88.04

x

5

89.04

x

10

100.00

x

20

100.00

x

30

100.00

Table 7.18: Dose profile agreement between the TrueBeam FFF 6MV multiple source model
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a
20 x 20 cm2 field size.
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Figure 7.71: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
6MV beam at a field size of 30 x 30 cm2.

Field Size (cm2)

30 x 30

Direction Depth (cm)

% Passing (2%/2mm)

x

1.5

88.04

x

5

89.04

x

10

100.00

x

20

100.00

x

30

100.00

Table 7.19: Dose profile agreement between the TrueBeam FFF 6MV multiple source model
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a
30 x 30 cm2 field size.
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Figure 7.72: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
6MV beam at a field size of 40 x 40 cm2.

Field Size (cm2)

40 x 40

Direction Depth (cm)

% Passing (2%/2mm)

x

1.5

89.91

x

5

90.50

x

10

100.00

x

20

100.00

x

30

100.00

Table 7.20: Dose profile agreement between the TrueBeam FFF 6MV multiple source model
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a
40 x 40 cm2 field size.
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7.6 Varian TrueBeam 6 MV: Gamma Maps
7.6.1 Varian TrueBeam 6 MV: Delivery of IMRT Head and Neck Plan

Figure 7.73: IMRT head and neck delivery comparison for the axial plane of delivery #2 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
89.4% of pixels passed.
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Figure 7.74: IMRT head and neck delivery comparison for the sagittal plane of delivery #2 for
the TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 86.6% of pixels passed.

Figure 7.75: IMRT head and neck delivery comparison for the axial plane of delivery #3 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
80.3% of pixels passed.
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Figure 7.76: IMRT head and neck delivery comparison for the sagittal plane of delivery #3 for
the TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 95.9% of pixels passed.
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7.6.2 Varian TrueBeam 6 MV: Delivery of SBRT Lung Plan

Figure 7.77: Lung SBRT delivery comparison for the axial plane of delivery #2 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
84.5% of pixels passed.
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Figure 7.78: Lung SBRT delivery comparison for the sagittal plane of delivery #2 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
90.3% of pixels passed.

Figure 7.79: Lung SBRT delivery comparison for the coronal plane of delivery #2 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
98.4% of pixels passed.
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Figure 7.80: Lung SBRT delivery comparison for the axial plane of delivery #3 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
87.5% of pixels passed.

Figure 7.81: Lung SBRT delivery comparison for the sagittal plane of delivery #3 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
95.2% of pixels passed.
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Figure 7.82: Lung SBRT delivery comparison for the coronal plane of delivery #3 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
85.5% of pixels passed.
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7.6.3 Varian TrueBeam 6 MV: Delivery of IMRT Lung Plan

Figure 7.83: Lung IMRT delivery comparison for the axial plane of delivery #2 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
91.4% of pixels passed.

217

Figure 7.84: Lung IMRT delivery comparison for the sagittal plane of delivery #2 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
87.4% of pixels passed.

Figure 7.85: Lung IMRT delivery comparison for the coronal plane of delivery #2 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
88.4% of pixels passed.
218

Figure 7.86: Lung IMRT delivery comparison for the axial plane of delivery #3 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
93.5% of pixels passed.

Figure 7.87: Lung IMRT delivery comparison for the sagittal plane of delivery #3 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
94.3% of pixels passed.
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Figure 7.88: Lung IMRT delivery comparison for the coronal plane of delivery #3 for the
TrueBeam FFF 6MV model. Agreement was evaluated using a ±3%/2mm gamma criterion and
92.4% of pixels passed.
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7.7 Varian TrueBeam 10 MV: Percent Depth Dose and Dose Profiles

Figure 7.89: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a
TrueBeam FFF 10MV beam at a field size of 3 x 3 cm2. Gamma agreement (red circles) for
each point is also displayed along with any points (red star) at which a failure to meet the
±2%/2mm criterion. At this field size 99.3% of all data passed the gamma criterion.
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Figure 7.90: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a
TrueBeam FFF 10MV beam at a field size of 4 x 4 cm2. Gamma agreement (red circles) for
each point is also displayed along with any points (red star) at which a failure to meet the
±2%/2mm criterion. At this field size 99.3% of all data passed the gamma criterion.

Figure 7.91: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a
TrueBeam FFF 10MV beam at a field size of 6 x 6 cm2. Gamma agreement (red circles) for
each point is also displayed along with any points (red star) at which a failure to meet the
±2%/2mm criterion. At this field size 99.3% of all data passed the gamma criterion.
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Figure 7.92: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a
TrueBeam FFF 10MV beam at a field size of 8 x 8 cm2. Gamma agreement (red circles) for
each point is also displayed along with any points (red star) at which a failure to meet the
±2%/2mm criterion. At this field size 100.0% of all data passed the gamma criterion.

Figure 7.93: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a
TrueBeam FFF 10MV beam at a field size of 10 x 10 cm2. Gamma agreement (red circles) for
each point is also displayed along with any points (red star) at which a failure to meet the
±2%/2mm criterion. At this field size 100.0% of all data passed the gamma criterion.
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Figure 7.94: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a
TrueBeam FFF 10MV beam at a field size of 20 x 20 cm2. Gamma agreement (red circles) for
each point is also displayed along with any points (red star) at which a failure to meet the
±2%/2mm criterion. At this field size 100.0% of all data passed the gamma criterion.

Figure 7.95: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a
TrueBeam FFF 10MV beam at a field size of 30 x 30 cm2. Gamma agreement (red circles) for
each point is also displayed along with any points (red star) at which a failure to meet the
±2%/2mm criterion. At this field size 97.4% of all data passed the gamma criterion.
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Figure 7.96: Calculated (blue ‘x’) and measured (red line) percent depth dose curves for a
TrueBeam FFF 10MV beam at a field size of 40 x 40 cm2. Gamma agreement (red circles) for
each point is also displayed along with any points (red star) at which a failure to meet the
±2%/2mm criterion. At this field size 96.7% of all data passed the gamma criterion.
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Figure 7.97: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
FFF 10MV beam at a field size of 3 x 3 cm2.

Field Size (cm2)

3x3

Direction Depth (cm)

% Passing (2%/2mm)

x

2.4

94.57

x

5

100.00

x

10

100.00

x

20

100.00

x

30

100.00

Table 7.21: Dose profile agreement between the TrueBeam FFF 10MV multiple source model
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 3
x 3 cm2 field size.
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Figure 7.98: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
FFF 10MV beam at a field size of 4 x 4 cm2.

Field Size (cm2)

4x4

Direction Depth (cm)

% Passing (2%/2mm)

x

2.4

100.00

x

5

98.56

x

10

100.00

x

20

100.00

x

30

100.00

Table 7.22: Dose profile agreement between the TrueBeam FFF 10MV multiple source model
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 4
x 4 cm2 field size.
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Figure 7.99: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
FFF 10MV beam at a field size of 6 x 6 cm2.

Field Size (cm2)

6x6

Direction Depth (cm)

% Passing (2%/2mm)

x

2.4

98.74

x

5

99.37

x

10

100.00

x

20

100.00

x

30

100.00

Table 7.23: Dose profile agreement between the TrueBeam FFF 10MV multiple source model
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 6
x 6 cm2 field size.
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Figure 7.100: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
FFF 10MV beam at a field size of 8 x 8 cm2.

Field Size (cm2)

8x8

Direction Depth (cm)

% Passing (2%/2mm)

x

2.4

96.10

x

5

98.88

x

10

96.65

x

20

100.00

x

30

100.00

Table 7.24: Dose profile agreement between the TrueBeam FFF 10MV multiple source model
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a 8
x 8 cm2 field size.
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Figure 7.101: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
FFF 10MV beam at a field size of 10 x 10 cm2.

Field Size (cm2)

10 x 10

Direction Depth (cm)

% Passing (2%/2mm)

x

2.4

93.47

x

5

96.98

x

10

90.45

x

20

100.00

x

30

100.00

Table 7.25: Dose profile agreement between the TrueBeam FFF 10MV multiple source model
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a
10 x 10 cm2 field size.
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Figure 7.102: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
FFF 10MV beam at a field size of 20 x 20 cm2.

Field Size (cm2)

20 x 20

Direction Depth (cm)

% Passing (2%/2mm)

x

2.4

99.67

x

5

93.07

x

10

100.00

x

20

100.00

x

30

100.00

Table 7.26: Dose profile agreement between the TrueBeam FFF 10MV multiple source model
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a
20 x 20 cm2 field size.
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Figure 7.103: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
FFF 10MV beam at a field size of 30 x 30 cm2.

Field Size (cm2)

30 x 30

Direction Depth (cm)

% Passing (2%/2mm)

x

2.4

90.17

x

5

90.42

x

10

100.00

x

20

100.00

x

30

100.00

Table 7.27: Dose profile agreement between the TrueBeam FFF 10MV multiple source model
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a
30 x 30 cm2 field size.
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Figure 7.104: Calculated (red circle) and measured (blue line) dose profiles for a TrueBeam
FFF 10MV beam at a field size of 40 x 40 cm2.

Field Size (cm2)

40 x 40

Direction Depth (cm)

% Passing (2%/2mm)

x

2.4

88.61

x

5

90.18

x

10

100.00

x

20

100.00

x

30

99.61

Table 7.28: Dose profile agreement between the TrueBeam FFF 10MV multiple source model
and measurement using a ±2%/2mm global gamma criterion at all depths of comparison for a
40 x 40 cm2 field size.
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7.8 Varian TrueBeam 10 MV: Gamma Maps
7.8.1 Varian TrueBeam 10 MV: Delivery of IMRT Head and Neck Plan

Figure 7.105: IMRT head and neck delivery comparison for the axial plane of delivery #2 for
the TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 93.1% of pixels passed.
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Figure 7.106: IMRT head and neck delivery comparison for the sagittal plane of delivery #2 for
the TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 85.9% of pixels passed.

Figure 7.107: IMRT head and neck delivery comparison for the axial plane of delivery #3 for
the TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 75.5% of pixels passed.
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Figure 7.108: IMRT head and neck delivery comparison for the sagittal plane of delivery #3 for
the TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 90.1% of pixels passed.
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7.8.2 Varian TrueBeam 10 MV: Delivery of SBRT Lung Plan

Figure 7.109: Lung SBRT delivery comparison for the axial plane of delivery #2 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 87.4% of pixels passed.
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Figure 7.110: Lung SBRT delivery comparison for the sagittal plane of delivery #2 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 88.1% of pixels passed.

Figure 7.111: Lung SBRT delivery comparison for the coronal plane of delivery #2 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 92.7% of pixels passed.
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Figure 7.112: Lung SBRT delivery comparison for the axial plane of delivery #3 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 95.8% of pixels passed.

Figure 7.113: Lung SBRT delivery comparison for the sagittal plane of delivery #3 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 91.4% of pixels passed.
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Figure 7.114: Lung SBRT delivery comparison for the coronal plane of delivery #3 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 98.1% of pixels passed.
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7.8.3 Varian TrueBeam 10 MV: Delivery of IMRT Lung Plan

Figure 7.115: Lung IMRT delivery comparison for the axial plane of delivery #1 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 95.6% of pixels passed.
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Figure 7.116: Lung IMRT delivery comparison for the sagittal plane of delivery #1 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 84.2% of pixels passed.

Figure 7.117: Lung IMRT delivery comparison for the coronal plane of delivery #1 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 92.1% of pixels passed.
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Figure 7.118: Lung IMRT delivery comparison for the axial plane of delivery #2 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 97.4% of pixels passed.

Figure 7.119: Lung IMRT delivery comparison for the sagittal plane of delivery #2 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 93.6% of pixels passed.
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Figure 7.120: Lung IMRT delivery comparison for the coronal plane of delivery #2 for the
TrueBeam FFF 10MV model. Agreement was evaluated using a ±3%/2mm gamma criterion
and 96.4% of pixels passed.
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7.9 Outside Institution Robustness Study: Gamma Maps
7.9.1 Head and Neck Phantom Audits

Figure 7.121: IMRT head and neck delivery comparison for the axial plane of Head and Neck
Plan #1 with respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm
gamma criterion and 59.1% of pixels passed.
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Figure 7.122: IMRT head and neck delivery comparison for the sagittal plane of Head and
Neck Plan #1 with respect to DPM recalculated dose. Agreement was evaluated using a
±3%/2mm gamma criterion and 69.4% of pixels passed.

Figure 7.123: IMRT head and neck delivery comparison for the axial plane of Head and Neck
Plan #1 with respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm
gamma criterion and 82.1% of pixels passed.
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Figure 7.124: IMRT head and neck delivery comparison for the sagittal plane of Head and
Neck Plan #1 with respect to DPM recalculated dose. Agreement was evaluated using a
±5%/3mm gamma criterion and 88.2% of pixels passed.

Figure 7.125: IMRT head and neck delivery comparison for the axial plane of Head and Neck
Plan #1 with respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm
gamma criterion and 67.6% of pixels passed.
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Figure 7.126: IMRT head and neck delivery comparison for the sagittal plane of Head and
Neck Plan #1 with respect to TPS calculated dose. Agreement was evaluated using a
±3%/2mm gamma criterion and 75.3% of pixels passed.

Figure 7.127: IMRT head and neck delivery comparison for the axial plane of Head and Neck
Plan #1 with respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm
gamma criterion and 88.6% of pixels passed.
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Figure 7.128: IMRT head and neck delivery comparison for the sagittal plane of Head and
Neck Plan #1 with respect to TPS calculated dose. Agreement was evaluated using a
±5%/3mm gamma criterion and 98.9% of pixels passed.

Figure 7.129: IMRT head and neck delivery comparison for the axial plane of Head and Neck
Plan #2 with respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm
gamma criterion and 88.4% of pixels passed.
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Figure 7.130: IMRT head and neck delivery comparison for the sagittal plane of Head and
Neck Plan #2 with respect to DPM recalculated dose. Agreement was evaluated using a
±3%/2mm gamma criterion and 52.5% of pixels passed.

Figure 7.131: IMRT head and neck delivery comparison for the axial plane of Head and Neck
Plan #2 with respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm
gamma criterion and 98.3% of pixels passed.
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Figure 7.132: IMRT head and neck delivery comparison for the sagittal plane of Head and
Neck Plan #2 with respect to DPM recalculated dose. Agreement was evaluated using a
±5%/3mm gamma criterion and 76.8% of pixels passed.

Figure 7.133: IMRT head and neck delivery comparison for the axial plane of Head and Neck
Plan #2 with respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm
gamma criterion and 85.9% of pixels passed.
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Figure 7.134: IMRT head and neck delivery comparison for the axial plane of Head and Neck
Plan #2 with respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm
gamma criterion and 69.8% of pixels passed.

Figure 7.135: IMRT head and neck delivery comparison for the sagittal plane of Head and
Neck Plan #2 with respect to TPS calculated dose. Agreement was evaluated using a
±5%/3mm gamma criterion and 98.4% of pixels passed.
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Figure 7.136: IMRT head and neck delivery comparison for the sagittal plane of Head and
Neck Plan #2 with respect to TPS calculated dose. Agreement was evaluated using a
±5%/3mm gamma criterion and 86.3% of pixels passed.
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7.9.2 Lung Phantom Audits

Figure 7.137: Lung phantom delivery comparison for the axial plane of Lung Plan #1 with
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma
criterion and 99.7% of pixels passed.
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Figure 7.138: Lung phantom delivery comparison for the coronal plane of Lung Plan #1 with
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma
criterion and 99.0% of pixels passed.

Figure 7.139: Lung phantom delivery comparison for the sagittal plane of Lung Plan #1 with
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma
criterion and 94.9% of pixels passed.
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Figure 7.140: Lung phantom delivery comparison for the axial plane of Lung Plan #1 with
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma
criterion and 99.9% of pixels passed.

Figure 7.141: Lung phantom delivery comparison for the coronal plane of Lung Plan #1 with
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma
criterion and 99.0% of pixels passed.
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Figure 7.142: Lung phantom delivery comparison for the sagittal plane of Lung Plan #1 with
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma
criterion and 99.6% of pixels passed.

Figure 7.143: Lung phantom delivery comparison for the axial plane of Lung Plan #1 with
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion
and 97.4% of pixels passed.
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Figure 7.144: Lung phantom delivery comparison for the coronal plane of Lung Plan #1 with
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion
and 95.5% of pixels passed.

Figure 7.145: Lung phantom delivery comparison for the sagittal plane of Lung Plan #1 with
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion
and 86.8% of pixels passed.
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Figure 7.146: Lung phantom delivery comparison for the axial plane of Lung Plan #1 with
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion
and 99.9% of pixels passed.

Figure 7.147: Lung phantom delivery comparison for the coronal plane of Lung Plan #1 with
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion
and 99.9% of pixels passed.
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Figure 7.148: Lung phantom delivery comparison for the sagittal plane of Lung Plan #1 with
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion
and 99.4% of pixels passed.

Figure 7.149: Lung phantom delivery comparison for the axial plane of Lung Plan #2 with
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma
criterion and 88.4% of pixels passed.
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Figure 7.150: Lung phantom delivery comparison for the coronal plane of Lung Plan #2 with
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma
criterion and 79.1% of pixels passed.

Figure 7.151: Lung phantom delivery comparison for the sagittal plane of Lung Plan #2 with
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma
criterion and 82.6% of pixels passed.
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Figure 7.152: Lung phantom delivery comparison for the axial plane of Lung Plan #2 with
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma
criterion and 99.0% of pixels passed.

Figure 7.153: Lung phantom delivery comparison for the coronal plane of Lung Plan #2 with
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma
criterion and 96.9% of pixels passed.
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Figure 7.154: Lung phantom delivery comparison for the sagittal plane of Lung Plan #2 with
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma
criterion and 99.5% of pixels passed.

Figure 7.155: Lung phantom delivery comparison for the axial plane of Lung Plan #2 with
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion
and 96.0% of pixels passed.
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Figure 7.156: Lung phantom delivery comparison for the coronal plane of Lung Plan #2 with
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion
and 93.3% of pixels passed.

Figure 7.157: Lung phantom delivery comparison for the sagittal plane of Lung Plan #2 with
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion
and 66.8% of pixels passed.
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Figure 7.158: Lung phantom delivery comparison for the axial plane of Lung Plan #2 with
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion
and 99.9% of pixels passed.

Figure 7.159: Lung phantom delivery comparison for the coronal plane of Lung Plan #2 with
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion
and 99.8% of pixels passed.
265

Figure 7.160: Lung phantom delivery comparison for the sagittal plane of Lung Plan #2 with
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion
and 93.2% of pixels passed.

Figure 7.161: Lung phantom delivery comparison for the axial plane of Lung Plan #3 with
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma
criterion and 92.1% of pixels passed.
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Figure 7.162: Lung phantom delivery comparison for the coronal plane of Lung Plan #3 with
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma
criterion and 92.6% of pixels passed.

Figure 7.163: Lung phantom delivery comparison for the sagittal plane of Lung Plan #3 with
respect to DPM recalculated dose. Agreement was evaluated using a ±3%/2mm gamma
criterion and 97.1% of pixels passed.
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Figure 7.164: Lung phantom delivery comparison for the axial plane of Lung Plan #3 with
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma
criterion and 99.1% of pixels passed.

Figure 7.165: Lung phantom delivery comparison for the coronal plane of Lung Plan #3 with
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma
criterion and 99.6% of pixels passed.
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Figure 7.166: Lung phantom delivery comparison for the sagittal plane of Lung Plan #3 with
respect to DPM recalculated dose. Agreement was evaluated using a ±5%/3mm gamma
criterion and 99.8% of pixels passed.

Figure 7.167: Lung phantom delivery comparison for the axial plane of Lung Plan #3 with
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion
and 64.1% of pixels passed.
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Figure 7.168: Lung phantom delivery comparison for the coronal plane of Lung Plan #3 with
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion
and 53.6% of pixels passed.

Figure 7.169: Lung phantom delivery comparison for the sagittal plane of Lung Plan #3 with
respect to TPS calculated dose. Agreement was evaluated using a ±3%/2mm gamma criterion
and 64.1% of pixels passed.
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Figure 7.170: Lung phantom delivery comparison for the axial plane of Lung Plan #3 with
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion
and 85.7% of pixels passed.

Figure 7.171: Lung phantom delivery comparison for the coronal plane of Lung Plan #3 with
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion
and 82.5% of pixels passed.
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Figure 7.172: Lung phantom delivery comparison for the sagittal plane of Lung Plan #3 with
respect to TPS calculated dose. Agreement was evaluated using a ±5%/3mm gamma criterion
and 82.4% of pixels passed.
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